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The EMCDDA presents, for the first time, a report exclu-
sively devoted to the drug phenomenon in the candidate
central and eastern European countries (CEECs). This is a
result of the cooperation that has been established with
its new partner countries and future members, with the
financial support of the Phare Programme.
The report shows a different picture than what was
known just five to seven years ago. At that time, these
countries were generally perceived as ‘transit’ countries
only, with all the associated stereotypes in terms of
‘danger’ posed to EU citizens. Today they have become a
clear target for the consumption of drugs.
The available data suggest that drug use is on the
increase, both for heroin, which is progressively replac-
ing the locally produced opiates, and for cannabis, which
is the most widely used drug in these countries,
especially for experimental and recreational use. An
increase in the use of synthetic drugs is also visible, a
proportion of which are exported from the EU to CEEC
markets. There is also evidence that high-risk behaviours
related to drug consumption are prevalent, and that there
is the potential for drug-related infectious diseases among
injecting drug users to spread. 
The phenomenon is occurring in a more general context
of exacerbated consumerist behaviour among young
people, which is also reflected in the use of licit
substances such as alcohol and tobacco. 
Within this context, candidate countries are facing a
double challenge of developing relevant legislative
measures, administrative and coordination structures,
and improving the coverage and range of the services
provided in line with the acquis communautaire and
taking into account the best practice developed in the
respective areas.
While the preparation for accession to the EU enables
them to benefit from the active support of the
Commission and the Member States in developing some
of these responses, they are facing huge difficulties in
implementing and financing over a few years what took
20 years in the EU and is still ongoing.
It should be noted that in the framework of the technical
cooperation established with the EMCDDA, it has been
observed by candidate countries that the acquis
communautaire on drugs was not always ‘strong’
enough to assist them in overcoming administrative and
legislative obstacles.
The challenge for an enlarged Union will be to help
new Member States to build together a more compre-
hensive and more sustainable response to this complex
phenomenon and will probably require new political
initiatives
This report reflects the willingness of the EMCDDA and
the new national focal points to contribute to the debate
by providing the European Commission, the Member
States and the candidate countries with a picture of the
phenomenon based on the scientific evidence avail-
able. Improving the quality and coverage of data is our
common challenge for the years to come.
Georges Estievenart
Executive Director
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The European Union Drugs Strategy (2000–2004), which
was adopted at the Helsinki European Council in
December 1999, emphasises the need for the progressive
integration of the candidate countries. In order to trans-
pose the strategy into concrete actions, in June 2000 the
Feira European Council adopted the EU Action Plan on
Drugs (2000–2004). The Action Plan foresees that the
European Commission will continue to support, with
technical assistance and finance where necessary, the
candidate countries in their fight against drug use and
drug trafficking. Particular emphasis is placed on the
development of national strategies, national drugs units,
focal points for the EMCDDA and effective controls on
drugs entering the EU and candidate countries. The Phare
Programme is similarly oriented. The EU Action Plan also
requires the Commission and the Council to ensure that
the candidate countries adopt the acquis communautaire
and best practice in the field of drugs, and that their
implementation is satisfactory. 
In March 2002, the Council mandated the Commission to
initiate negotiations with the candidate countries for their
participation in all the activities of the European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA). This participation will be possible on the
basis of a clause in the Centre’s constituent regulations
allowing it to be opened up to candidate countries to the
EU. At present, cooperation between the EMCDDA and
the candidate central and eastern European countries
(CEECs) is in a transitional period during which technical
support is being extended to include inter-institutional
cooperation and to establish permanent structural links.
In order to integrate the CEECs into the EMCDDA’s activi-
ties, work programme and institutional life, the
Phare–EMCDDA technical cooperation project, imple-
mented directly by the Centre, is supporting the establish-
ment of national drug information focal points.
The EMCDDA has published three chapters on the drug
situation in the CEECs in its 1998, 2000 and 2001 Annual
reports on the state of the drugs problem in the European
Union. In order to provide a more complete picture of the
drug phenomenon in the candidate countries to the EU,
the Phare project ‘Cooperation EMCDDA–CEECs’ has
initiated the production of this report. The report is
written mainly by experts from the candidate countries
and primarily covers the central and eastern European
countries which are actively involved in technical
cooperation with the EMCDDA. It makes use of the infor-
mation available through the 2001 national reports on the
Introduction 
drug situation produced by the candidate countries’
national drug information focal points. In the few
instances where data is available, reference is also made
to other candidate countries to the EU, such as Malta. 
The report primarily addresses the policymaking level,
both European and national, and is broadly structured
around the targets of the EU Action Plan on Drugs
(2000–2004). It focuses more in depth on two key issues
— treatment and drug-related infectious diseases — and
examines the availability of information and the limita-
tions and quality of available data. Wherever possible,
the report makes methodological references to the
EMCDDA technical tools and guidelines, such as the key
epidemiological indicators, and underlines the need for
their introduction and implementation at national level in
all candidate countries. 
The report confirms the major trends in drugs use,
patterns of use and responses as well as in the availability
and supply of drugs, as already identified by prior
EMCDDA reports, and also attempts to provide insight
into the underlying causes and possible explanations of
the observed processes. 
The report recognises that major drugs seizures along the
Balkan route and in central Europe confirm the role of the
region in the transportation and storage of heroin.
However, as heroin consumption increases, it seems that
the CEECs are increasingly becoming targets for distribu-
tion as well. Patterns of drug use are changing, with
imported heroin progressively taking the place of locally
produced opiates and other substances, while, at the
same time, use is spreading from major urban centres to
all regions. Consequently, heroin (which is predomi-
nantly injected) is the prevailing drug for problem drug
use, which explains the concurrent increase in the
demand for treatment for opiate dependency. 
Although injecting drug users in the central and eastern
European region seem to be relatively spared by the HIV
epidemic, which is considered as low level, treatment
data and research show that risk behaviours related to
drug consumption are highly prevalent. However, the
three Baltic states are more affected, with Latvia and, in
particular, Estonia recently witnessing an alarmingly rapid
increase in the spread of HIV infection among injecting
drug users. In 2002, a major outbreak of HIV infection
was recorded in one Lithuanian prison. Even though there
are considerable differences between the countries in the
I n t r o d u c t i o n
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region, many of them have implemented measures to
confine the spread of drug-related infectious diseases
(HIV infection, hepatitis C and hepatitis B) amongst
injecting drug users. Nevertheless, it is imperative to
improve the coverage and range of the services provided
and to introduce harm reduction measures into all
settings where drug use takes place, including, for
example, the prison system. 
Central and eastern Europe also continues to be a transit
region for cannabis destined for the EU Member States.
Studies show that cannabis is the most widely used drug
in the CEECs, especially in the context of experimental
and recreational use. Synthetic drugs are also becoming
increasingly popular with young people and so their
production has increased significantly. The worldwide
prevalence of ecstasy use has led to exportation of the
drug from the EU to markets in central and eastern
Europe. 
Within this context, the candidate central and eastern
European countries have taken substantial steps to develop
relevant legislative measures and administrative and coordi-
nation structures. In addition, as part of the process of EU
enlargement, the 10 candidate CEECs have adjusted their
drug control activities to adopt and implement the acquis
communautaire in the multifaceted field of drugs. 
All the candidate CEECs have signed and ratified the
three UN drug control conventions with Estonia being the
most recent country to ratify the 1988 ‘UN Convention
against Illicit Traffic in Narcotic Drugs and Psychotropic
Substances’ in 2000. The process of adopting national
legislation varies considerably throughout the region,
from the adoption of a number of laws addressing
specific drug-related issues such as prevention and treat-
ment of drug use, production and trade of illicit
substances, control of precursors, etc. (e.g. Hungary,
Slovenia), to the concept of a single, wide-ranging,
‘umbrella-type’ drug law in Poland and Bulgaria. Based
on individual implementation experiences and the need
to accede to the EU drugs acquis communautaire, some
of the newly adopted laws have already been reviewed,
fine-tuned or amended. In the Czech Republic and
Hungary, attempts have even been made to evaluate the
impact of these laws. 
In line with this new legislation, the national drug coordi-
nation and decision-making structures in most of the
candidate CEECs are undergoing dynamic change. After a
period without a functioning inter-ministerial coordinat-
ing body, the Council for Counteracting Drug Addiction
was constituted in June 2002 in Poland. Also in June
2002, the former National Drug Commission in the
Czech Republic was renamed the Governmental Council
for Drug Policy Coordination, while retaining and even
expanding its functions. 
The Hungarian Drugs Coordination Commission was
reformed in 1999 with a stronger mandate and improved
operational capacity. New laws passed in Slovenia and
Bulgaria in 1999 re-established the inter-ministerial
coordinating bodies in these countries and enhanced
their role through the creation of permanent support
structures — the Governmental Drugs Office and the
National Drug Council Secretariat — similar to those in
the Czech Republic, Slovakia and Latvia. The Romanian
Inter-ministerial Committee for the Fight against Drugs
was formally established in 1999 and is in the process of
being organised. Although already established in 1996,
the Estonian Ministers’ Committee on Drug Policy has yet
to start operating. The status and functions of the
Lithuanian Governmental Drug Control Commission are
being re-examined. Most of this reorganisation is
enabling these countries to set up structures that meet the
specific needs of a changing society and the problems it
is confronted with.
The leadership of these inter-ministerial coordinating
bodies is usually taken up by one of the relevant
ministries. In most of the countries, this is a ministry
dealing with social matters — the Ministry of Health in
Bulgaria, Lithuania and Slovenia, the Ministry of Social
Affairs in Estonia, and the Ministry of Youth and Sports in
Hungary. In other countries, it is the direct responsibility
of the government — chaired by the Prime Minister in the
Czech Republic and the Deputy Prime Minister in
Slovakia. It is the responsibility of the Ministry of the
Interior in Latvia. In Romania, the inter-ministerial body
is, by definition, ‘under the leadership’ of the Prime
Minister, but its work is organised by the Ministry of the
Interior. 
For the purpose of implementing and coordinating
national policy at local level, decentralised drug coordi-
nation structures are being set up. For example, the local
drug commissions in the Czech Republic were estab-
lished in 1994, the regional and district drug commis-
sions in Slovakia in 1997, and the municipal drugs
councils in Bulgaria in 2001. 
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As with most of the EU Member States, the develop-
ment of drug policies and strategies in the central and
eastern European countries since the mid-1990s has
been influenced by two factors: the changing nature of
the drug phenomenon, which increasingly affects
broader segments of society; and the multidimensional
character of the problem, which demands a nationally
coordinated response across all sectors. Over this
period, the initiatives of various international organisa-
tions, most notably the European Commission, have
been a catalyst for the development of national
responses to the drug phenomenon. 
In countries where the inter-ministerial drugs body is well
established, multidisciplinary national strategies are
elaborated and implemented. The Czech Republic, for
example, has adopted its third consecutive national strat-
egy, the first one having been adopted already in 1993.
The process of elaborating strategic documents and
action plans intensified in 1999, and national drug strate-
gies were adopted in Slovakia (1999), Poland (1999),
Hungary (2000) and the Czech Republic (2000). National
drug strategies are currently being elaborated, and will be
adopted by the end of 2002, in Bulgaria, Estonia, Latvia,
Lithuania, Poland, Romania, Slovakia and Slovenia. In
most cases the elaboration of these strategies is supported
by experts from EU Member States in the framework of
the EC-funded Phare national (twinning) drug project.
This positive approach to developing national strategies,
in general, demonstrates the commitment of the CEECs’
governments and shows that the drug problem is
acknowledged at political level. Most of the recently
adopted strategy documents are concrete action plans,
stating the objectives, targets, achievement indicators
and financial requirements for implementing the policy.
The need for improved information on drugs and evalua-
tion of interventions is increasingly recognised and
integrated into the national action plans, resulting also in
the establishment of the EMCDDA national drug infor-
mation focal points (see the list of national focal points
annexed to this report). The European Commission,
through the twinning projects between EU Member
States and candidate countries, and the EMCDDA are
currently supporting the elaboration of national action
plans for the development of national drug information
systems in all candidate CEECs.
The partnership between governmental and non-govern-
mental sectors in policy development and programme
implementation appears increasingly to be responding to
the individual and collective needs of the general popula-
tion, as well as to the drug-using population. All new
drugs strategies in the candidate countries are striving to
ensure consistency between domestic policies and those
endorsed at EU level.
Despite the fact that, in general, the legal and institutional
framework for national drugs strategies is in place in the
candidate CEECs, the capacity to implement effectively
the adopted measures is limited and the resources
allocated are in general insufficient. The low operational
level of the national coordination mechanisms in some
countries obstructs the effectiveness of policy implemen-
tation, and regional cooperation is still lacking. It is there-
fore essential that the countries concerned continue to
reinforce their policies, institutions and coordination
mechanisms and allocate additional resources to this
end. It should also be underlined that the efforts of the
candidate countries to align their actions in the drugs
field with those of the EU and its Member States are worth
not only recognition but continuing support. 
9C h a p t e r 1
Experimental and recreational
drug use and responses
Introduction
This chapter presents and comments on the available
data and information related to experimental and recre-
ational drug use in the candidate CEECs, and attempts to
correlate this information with the prevention activities.
Experimental and recreational drug use
Experimental drug use
Experimental drug use describes the use of an illicit drug,
usually only once or very few times, for experimental
purposes. This category includes all cases of incidental or
non-incidental (but not repeated) use of illegal substances,
mostly prompted by curiosity and/or a desire to experiment.
In surveys, this behaviour is usually covered by the category
‘lifetime prevalence’, which means ‘any use during a
person’s life’.
Recreational drug use
Recreational drug use describes more frequent use of
substances which have become attributes of modern
lifestyles for leisure and relaxation (e.g. cannabis, ecstasy,
LSD). Important characteristics of this category are a lack of
dependency, an absence of serious excesses and a
frequency of use that could be categorised as ‘sometimes’or
‘periodically’. 
In surveys, this use may be expressed as ‘use in the last 12
months’ or ‘use in the last 30 days’. However, to become a
‘recreational drug user’ means an increased likelihood of
becoming a ‘problem drug user’ in the future. (This group is
the subject of chapter 2.)
How to monitor the extent 
of this phenomenon
The spread of the phenomenon of experimental and recre-
ational drug use is uneven and varies across different
countries, regions, types of area, age, social and cultural
groups, etc. It is difficult to monitor for a number of reasons.
• Experimental drug use is engaged in by quite differ-
ent groups in varied situations and has a very
heterogeneous social basis.
• Experimental drug use is mainly incidental, and
people can tend to ‘forget’ such an episode when
answering questionnaires. 
• In principle, recreational use is non-problematic, so
it is not detected by the more traditional indicators
of problems (e.g. demand for treatment).
• Recreational use is limited to specific age groups
and cultural settings and therefore may not be suffi-
ciently reflected in nationwide surveys.
• Recreational use is occasional, usually focused on
special events and occasions, such as weekends and
festivals. This is why targeted surveys and observa-
tions are important for the planning of services and
responses.
• Recreational use is socially integrated, rather than
being the problem of a socially deprived minority. It
is therefore not perceived and not reported as a
problem by those who engage in it.
In order to get a picture of the extent of this phenomenon,
it is possible to obtain information either by representa-
tive school and general population surveys, or by focused
studies, generally qualitative research. Most of the infor-
mation presented in this chapter comes from general
population surveys and school surveys.
What is known about experimental 
and recreational drug use in the CEECs?
As with the EU Member States, recreational use and
experimentation is increasingly becoming an integral part
of youth culture in most of the candidate countries. Also,
the substances used and the patterns of use are very
similar.
In most of the CEECs, the use and patterns of use of
experimental and recreational drugs are relatively new
social phenomena, which is why studies and reliable
data are scarce. Another important factor is that national
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In Poland, 10 % of people took an illicit substance at least
once in the past year, with 1.1 % of these using drugs
other than cannabis derivatives. Comparison between
studies made in 1994 and 1998 shows a considerable
increase in drug use. In 1994, only 1.4 % of respondents
reported having tried any kind of drug during their
lifetime; by 1998, this had increased to almost 7 %.
In the vast majority of cases, experience with drugs in
Poland was limited to experimenting with cannabis deriv-
atives. Some respondents to the survey, however, had
also experimented with other substances, mainly amphet-
amine and hallucinogens.
In Slovakia, it is significant that the population survey
reflected the fact that, between 1994 and 1996, the
already substantial number of people that had used
some illegal drugs at least once in their lives had
doubled. Another survey suggested that this sharp
increase had stopped by 1998, but more recent data
does not corroborate this. Increasing growth in drug use
among young Slovaks appears to have been constant
between 1994 and 2000.
Experimental use is on the increase among young people
in general, while recreational use, particularly in urban
areas, is spreading. 
Comparison of the results from the European school
survey project on alcohol and other drugs (ESPAD) 1995
and 1999 indicate that the number of 15- to 16-year-old
students experimenting with illegal drugs had doubled in
Estonia, Hungary, Poland, Slovakia and Slovenia, and
had increased fivefold in Lithuania. 
In the Czech Republic, where drug use was already
high, prevalence increased one-and-a-half times. In
general population surveys are expensive and their
relevance has to be fully appreciated in order for funding
to be secured. In fact, national studies indicating drug
consumption are only reported by five out of the ten
candidate CEECs (the Czech Republic, Estonia, Hungary,
Poland and Slovakia). 
In this situation, it is difficult to ascertain the extent of the
problem in order to identify some common factors and
make comparisons. Nevertheless, several sources of data
do exist which give basic information on the phenomenon.
There has been an increase in experimental drug use in
the general population, which is indicated by the
increase in lifetime prevalence. This means that the
number of people who have tried illicit drugs (in the
general population, as well as young people and
students) during their lifetime has increased. The data
available show that this is true for all the ten candidate
CEECs, particularly Bulgaria, the Czech Republic,
Estonia, Romania, Slovakia and Slovenia.
Data related to the use of different substances in the
Czech Republic show that, during the period
1996–1999, experimentation with cannabis increased
from 14.2 to 16.4 %. The data sources are surveys
among the general adult population in the country (15-
64 years of age). An interesting trend was reported in
experimentation with amphetamines, which decreased
from 2.6 to 1 %. However, at the end of the same
period, another synthetic drug for recreational use —
ecstasy — appeared on the scene (0.9 %). Other
substances are characterised by a relatively stable level
of use, or at least a lack of any visible trend: opiate use
being in the range of 0.5 to 1.2 %, and hallucinogens
between 1.7 and 2.2 %.
A first impression of the experimental use of illicit drugs
in Estonia is based on a national survey that was carried
out at the end of 1998. According to this, 7 % of people
aged 18–70 reported having tried drugs at least once in
their lifetime. The gender breakdown was 11 % of men
and 3 % of women of the same age reporting having
used drugs at least once. As in all countries, among
younger people, the percentage of those who had tried
drugs was considerably higher: 25 % of males and 9 % of
females among 18- to 24-year-olds, and 17 % and 5 %,
respectively, among 25- to 34-year-olds.
Cannabis is the most frequently experimented drug in
Estonia, with 5 % of the population (8 % of men and 2 %
of women) using it during their lifetime. This compares to
a 1 % lifetime consumption of other substances.
Table 1: Lifetime experience of ecstasy, amphetamines and LSD use
among schoolchildren (%) – ESPAD 1995–1999
1995 1999 1995 1999 1995 1999
Bulgaria – 1 – 1 – 1
Czech Republic 0 4 2 5 2 7
Estonia 0 3 0 7 1 3
Former Yugoslav  
– 1 – 0 – 1Republic of Macedonia
Hungary 1 3 0 2 1 4
Latvia 0 6 0 4 0 4
Lithuania 0 4 0 2 0 2
Poland 0 3 2 7 1 5
Romania – 0 – 0 – 0
Slovakia – 2 0 1 0 4
Slovenia 1 4 0 1 1 3
Ecstasy Amphetamines LSD
E x p e r i m e n t a l  a n d  r e c r e a t i o n a l  d r u g  u s e  a n d  r e s p o n s e s
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evolution of social perceptions, this might indicate
there is still a potential for growth in experimentation
with drugs in the central and eastern European
societies.
Data collected nationally, both in the general and
school population, may not adequately capture some
groups such as ethnic minorities, school drop-outs, the
homeless and the unemployed. In order to facilitate the
development of tailored prevention programmes, it is
necessary to further develop existing monitoring
systems to make them more appropriate for specific
groups exposed to the risk of developing drug
problems.
Targeted responses to experimental
and recreational use 
The design and implementation of appropriate
responses to experimental and recreational drug use,
usually through prevention programmes, faces a huge
challenge in light of increasing use of licit and illicit
substances, as described previously, especially bearing
in mind that the top two answers from schoolchildren
concerning the reasons for their first use was ‘I was
curious’, and ‘I wanted to feel high’.
It must be remembered that most recreational users are
well integrated into society. They manage their usage
according to the mood and circumstances of the
moment, changing the drugs they use or even mixing
drugs, according to availability. Their usage is also
affected by how established the pattern of drug use is.
Behaviour of this type, reflecting a well developed
sense of individualism, makes it particularly difficult for
prevention messages to reach this group.
Our knowledge of the influencing factors behind exper-
imental and recreational drug use, and consequently
potential prevention strategies, is very limited, making
it difficult to tailor prevention programmes aimed at
this population.
A study, ‘The use of drugs within the techno party scene
in European metropolitan cities’ (Tossmann et al.,
2001), was conducted in 1998 among a total of 3 503
visitors to techno parties in Amsterdam, Berlin, Madrid,
Prague, Rome, Vienna and Zurich. The study clearly
shows the huge discrepancy between figures obtained
in nationwide surveys and those obtained in more
focused and targeted settings. It also illustrates the need
to link the research and prevention strategies to the
1999, the first year of their participation in ESPAD, the
percentages of schoolchildren who admitted having
tried an illicit drug at least once was 14 % in Bulgaria,
21 % in Latvia and 12 % in Romania. This allows some
countries, such as Lithuania, to define drug use as a new
social phenomenon.
The increase in lifetime prevalence of ‘high-risk’ drug
use is less marked than for cannabis-type drugs. Solvent
use is decreasing in schools, probably not because the
relevant age cohort (16 years) is decreasing its usage of
the drug but because an increasing stratification in
society means the children of marginalised groups are
no longer present in the school population.
Drug use among young 
people in Lithuania
The largest at-risk social group in Lithuania is urban
youth, between the ages of 15 and 25, that equate
consumption of drugs with relaxation. They tend to
be fashion and music conscious, attend discotheques
and use stimulants experimentally. They are from
well-to-do families, may be studying or working, are
not involved in criminal activities and do not
consider drug consumption to be dangerous or risky.
The social perceptions of experimentation with some
substances is changing, and suggests the emergence of
a clear distinction between cannabis and other
substances. For instance, school surveys suggest that an
ever-increasing number of sixteen-year-olds believe
cannabis to be no more harmful than legal drugs and
population surveys of older age cohorts show less
repressive attitudes towards cannabis usage. Attitudes
to other illicit drug use did not change much during the
1990s.
The lifetime prevalence of legal drug use (tobacco and
alcohol) in the candidate countries is extremely high
and the age of both onset of alcohol use and first drunk-
enness is very low when compared with Member
States. For instance, while a recent survey in the Czech
Republic recorded 34 % of 16-years-olds smoking
marihuana at least once in their lives, 90 % of them
had drunk alcohol in the preceding month and 20 % of
them admitted to having been seriously drunk.
According to available analysis, early onset of alcohol
and/or tobacco use significantly increases the probabil-
ity of use of illicit drugs, including high-risk ones.
Combined with the information available related to the
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target group in order to design more appropriate
solutions. 
Among the conclusions of this study concerning the
impact of the new data on future prevention
programmes, it is worth reiterating the authors’ conclu-
sions: ‘the lifestyle and milieu of the target group
should be taken into account and, as far as possible,
target groups should take part in working out these
measures. However, target group orientation, in this
case, also means that the onset of programmes should
be at the location of target groups’.
Some recent developments in prevention 
in the candidate countries
There is considerable variation between the different
countries in addressing drug-related problems among
young people. There are also many diverse actors in the
field and prevention programmes and activities are at
different stages of development. This is reflected in the
available information concerning prevention
programmes and activities in most of the candidate
countries.
• In most countries, the main prevention activities take
place in schools. The focus seems to be primarily on
the delivery of a standard message about drugs, but
there is no information about the relevance of this
message to specific local problems. However, in some
countries the issue of evaluation is emerging as a
matter that demands consideration (see the section
‘School programmes’).
• There are drug prevention messages being promoted
through the mass media, but these are often too
general to reach local sub-groups and individuals.
Mass media information campaigns would seem to
offer potential not only for prevention purposes but
also for raising awareness generally and highlighting
the need for more appropriate responses from
society as a whole (see the section ‘Work with the
media’).
• It is worth stressing that both data collection and the
organisation of relevant responses are best carried out
at local or regional level, provided all the actors can be
mobilised towards a common goal. This is one of the
areas where the candidate countries have been very
active (see the section ‘Activities at community level’).
School programmes
In Bulgaria, prevention activities take place in secondary
schools and are targeted at the whole student body. They
aim to acquaint students (depending on their age) with
the main drugs, their effects and the harm they can cause
both ‘psychically and psychologically’.
Since 1998, the Czech Republic has implemented
‘Minimal Preventative Programmes’, under the
auspices of the Ministry of Education, Youth and Sport,
in all primary, secondary and high schools, aiming to
incorporate prevention measures into school life and
education.
In Estonia, the goal of prevention work is to increase
young people’s knowledge about drugs and drug addic-
tion. In the fifth grade, the curriculum introduces drug
prevention in the context of a general health education
programme. The main topics of the programme are
alcohol, drugs and their impact on the health of the
young, age group influences, self-help studies and how
to avoid alcohol and drug use. School staff, students,
parents and the public are all involved.
In 2000, about 40 % of schools in Hungary were active
in prevention and health promotion, although the
content was uneven in its quality and presentation.
Various prevention subjects were presented, with differ-
ent emphases. Less than 4–5 % of schools adopted in-
depth health promotion programmes in 2000. While, in
principle, prevention activities are mandatory in all
schools, in practice they are only randomly present as a
permanent attribute of the curriculum.
In Latvia, the theme of dependency prevention is
integrated into the basic national curriculum. The
programmes offered are addressed to all teachers and
they devote one lesson per week to prevention activities
(the so-called ‘educational lesson’). A Teachers’ guide
has been prepared for teachers of health studies at
primary school level, which focuses on physical,
emotional and social changes during puberty. The guide
includes methodological material on issues related to
substance abuse. In the fifth grade curriculum, the
questions of drug prevention are included in general
health education (which is a compulsory subject).
In Lithuanian schools, primary prevention of drug abuse
is usually included in health promotion programmes.
School health programmes are currently implemented
in only 50 schools, but a national network of ‘healthy’
schools is under development. Some special training
activities for teachers have been organised, and teach-
ing materials and guidelines on substance abuse
prevention in schools were provided. In 1998 and 1999,
a primary health care curriculum pilot project was
adopted in Klaipeda and, a year later, the curriculum
was introduced into a further 28 secondary schools in
the country. Special schools programmes are needed,
due to the rapid increase in drug abuse in schools.
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In Poland, the schools prevention programme targets
the promotion of healthy lifestyles and encourages
character development. Traditional methods, such as
lectures and presentations, are combined with more
active forms of group work, such as training, discussion
and brainstorming.
In Romania, schools have an optional curriculum
choice on themes related to the prevention of drug
abuse. Seventeen thousand copies of the World Health
Organisation’s manual, Young people and drug use,
were printed and distributed to all urban schools.
Training programmes based on this manual have also
been offered to teachers.
In Slovakia, a support book, How do I know myself?,
has been made available to 50 % of pupils at second
grade elementary level (5th, 6th and 7th classes).
Teachers evaluated this book positively for age and
didactic appropriateness. It was also deemed suitable
for systematic usage at second grade level. In secondary
schools, drug prevention was formally incorporated into
the curriculum, as well as into the lesson plans of drug
prevention coordinators, educational counsellors and
leading head teachers.
In Slovenia, a group of professionals has prepared a new
cross-curricular teaching aid called ‘Education for
health’. It is intended that the new system will be fully
operational by 2003/2004. Aims and topics were identi-
fied for every age group, including the use and abuse of
substances. A booklet was published containing the
curriculum proposal plus suggested literature for teach-
ers and pupils.
Work with the media
Not enough data exists about drug-oriented mass-media
campaigns. Furthermore, it seems that a significant propor-
tion do not emanate from any centralised and consistent
policy base. 
Most of the countries that are running general prevention
activities have had these reported by the media. While this
is a very important factor in the fight against drug abuse, it
cannot really be considered a mass-media campaign.
Two common trends can be mentioned for 2000 and
preceding years.
• In practice, all the well-known mass-media campaigns
were dedicated to a day, or period, in the national or
international calendar, such as the European Drug
Prevention Week, the United Nations International Day
Against Drug Abuse and Illicit Trafficking on 26 June or
‘Mental Health Week’ (annually each September).
• As well as campaigns in almost all the CEECs, the total
number of publications and articles on drug-related
themes in the media has increased as a whole. The media
involved and the themes covered have expanded as well.
Evaluation of prevention programmes
In Hungary, a research project was financed by the
Drug Coordination Department of the Youth and Sport
Ministry for the evaluation of school prevention
programmes in the city of Budapest in 2001. The
direct aim of this project was to analyse and evaluate
school prevention programmes operating in Budapest,
targeted directly at students (5th to 12th grade). The
research provided a detailed and systematic descrip-
tion of school prevention programmes in Budapest. It
shows the process and outcome evaluation of a
narrow range of the programmes and summarises the
methodology of planning and evaluating prevention
interventions. These conclusions will serve as a refer-
ence for future studies, as well as for the design of new
evaluation projects.
Lithuania
In Lithuania, a training programme organised for
journalists with the support of the Phare Programme
had a great impact on the way the press deals with the
subject. The results of the training are described below:
• a network of journalists, at national and local level,
writing about drug-related problems was established;
• contacts between journalists and professionals were
improved;
• journalists are now informed about global drugs
phenomena;
• journalists can assist NGOs;
• journalists are more professional in their analysis of
drug-related problems; and
• journalists now seek professional advice when they
are preparing a paper on the subject.
Activities at community level
Some countries are currently implementing very interest-
ing projects at regional and local level, some of which,
like those in Hungary, are supported by the Phare
Programme. Although these programmes are not only
oriented towards recreational drug users, they could form
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In Estonia, a total of 107 drug prevention activities were
organised in 16 local municipalities. A pilot project aimed at
assessing the drug prevention network and the main
problems at municipal level was also launched. Two training
courses were organised for civil servants, social workers,
doctors, policemen and probation officers of local municipal-
ities. On the basis of the foregoing, regular training courses
were started.
In Hungary, the engine driving drug policy in local communi-
ties is the Drug Consultation Forum (KEF), which coordinates
local actions and initiatives and serves as a forum for local
institutions in line with national objectives. Local Drug
Coordination Fora were set up in 56 cities in seven regions of
the country (with the support of the Ministry of Youth and
Sports through a tendering process). Local governments
showed keen interest in the tender. A very promising project
will start in September 2002, within the framework of the
Phare twinning assistance scheme. This project will improve
the coordination and technical capacities of the KEFs.
In Latvia, programmes for the prevention of drug abuse
have been formulated by the local governments of four
cities: Riga, Jelgava, Liepa¯ja and Ventspils. An integrated
approach to drug abuse prevention was developed and
general health care workers, social sector employees and
education personnel are actively involved in addressing
the abuse problem.
The city of Klaipeda’s Primary Prevention on Drug
Demand Reduction became a model in Lithuania and was
adapted by other local communities in the country. Funds
from several different international organisations have
supported three other model programmes, in Druskininkai,
Vilnius and Kaunas. These programmes are aimed at
increasing awareness, enhancing primary prevention and
related facilities in the community and disseminating infor-
mation on drug-related problems. The National Drug
Prevention Programme has recommended that prevention
programmes be implemented in each community.
Poland, in its national report on the drug problem, identi-
fies a primary goal of prevention activity as the creation of
coordinated teams in municipalities, administrative
districts and provinces. Their other finding, related to the
primary prevention of experimental and recreational use,
is more or less common to all countries and concerns
improving the skills of individuals responsible for coordi-
nating these activities at community level.
References
Tossmann, P., Boldt, S. and Tensil, M. D. (2001): ‘The use of drugs
within the techno party scene in European metropolitan cities’,
European Addiction Research, 7(1), pp. 2–23.
Bulgaria
A study on the articles dealing with drug trafficking, drug
distribution and prevention in four national daily
newspapers in 2000 and 2001 in Bulgaria shows that
the total number of such articles was 1 972. The results
of the study indicated that the most frequent topics were:
• prevention and consequences of drug abuse;
• reports about places where drug addicts gather, from
treatment centres for drug addicts to places where
juvenile drug users can talk in confidence about their
abuse;
• the sale of alcohol and cigarettes near schools, homes
for infants and juveniles and youth discos;
• the ‘tragic’ relationship between drugs and AIDS;
• meetings and seminars, at home and abroad,
dedicated to combating drug addiction; and
• opinions by respected specialists in the field —
doctors, psychiatrists and sociologists — on the distri-
bution of drugs among young people and the efforts
being made to restrict it.
a good basis for developing further specific preventive
actions adapted to the specific conditions of recreational
drug use in the various countries.
A new network of fourteen regional drug coordinators,
part of the regional government administrative system, has
been created in the Czech Republic. There have also been
reforms of the administrative department, as required by
EU regulations. Despite the fact that there had been 82
local coordinators in the old system, the new regime
places more demands on the knowledge and expertise of
regional coordinators. A special training programme has
been prepared for them by the National Drug Commission
and the future national focal point in close cooperation
with the EMCDDA Reitox and Enlargement Coordination.
This will cover the following areas:
• understanding the role of the EMCDDA and the
national focal point and their possible use in regional
policy-making;
• horizontal and vertical coordination of national drug
policy;
• management of drug policy decision-making (network-
ing, for the best use of limited resources);
• understanding five key indicators, their mutual relation-
ships and possible interpretations at regional level; and
• case studies and practical exercises.
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Problem drug use 
and treatment responses
Introduction
Even if data quality and availability differ a lot between
candidate countries and the resulting picture is rather
patchy, we can hypothesise that, in the last decade, candi-
date countries have experienced accelerated growth in
problem drug use and treatment responses similar to that
experienced by EU Member States over the last 35 years.
Not every candidate country is at the same stage of this
process (which is also true for the Member States), since the
geographical, economic and historical conditions are quite
different between countries, but the increase in problem
drug use and in responses is generally concordant.
Since the illicit drug market is clearly part of the ‘global’
market, a process of ‘westernisation’ of the previously
closed national scenes of all candidate countries is occur-
ring, with local specifics increasingly being eroded. At the
same time, some of the traditional local drugs have the
potential to be exported to the Member States and
elsewhere — Czech pervitin represents the best example of
this and various amphetamine-type drugs (ATD) from
Poland are another.
The treatment response in most CEECs is also beginning to
mirror the EU model, with substantial involvement of recog-
nised non-governmental organisations (NGOs) and other
bodies. According to available data, the CEECs that are
most advanced in this respect are the Czech Republic,
Hungary, Poland and Slovenia.
Last but not least, it is important to stress the need to
improve data gathering and monitoring systems in all candi-
date countries. Compared to the EU Member States, the
average level of data quality and availability is substantially
lower, though with few exceptions. The political support of
each government is a priority, as, without quality data, it is
impossible to evaluate interventions and policies — the
priority target of the EU Action Plan on Drugs (2000–2004).
Problem drug use
Problem drug users represent a very small minority of the
whole population, compared with people who have ever
used any illicit drug in their lifetime or with people who
currently use illicit drugs (see Figure 1). 
Drug-use surveys throughout the world have found the
percentage of problem drug use to be much smaller than
levels of current use, and these, in turn, are much lower
than levels of lifetime prevalence. In striking contrast to this
is the fact that problem drug use — as defined by the
EMCDDA (1) — is responsible for the vast majority of (or
almost all) harms associated with any drug use (health
problems, and social and economic cost to the society and
the individual concerned). Indeed, problem drug users
suffer extensively from all the potentially negative conse-
quences of their behaviour — from deaths by overdose and
other types of mortality, to drug-related infectious diseases
(such as HIV/AIDS and different types of viral hepatitis), to
socio-economic distress and addiction, which, together
with the high price of illegal drugs, leads to various kinds of
criminality — especially small-scale drug dealing and
property crimes (2) — ultimately resulting in prison
sentences in a substantial number of cases.
Problem drug use thus largely corresponds to the
(economic) definition of drug abuse: ‘Drug abuse exists
when drug use involves a net social cost additional to the
resource costs of the provision of that drug’ (Single et al.,
2001). As such, problem drug use and its economic conse-
quences is increasingly attracting the attention of relevant
decision-makers. The first target of the European Union
Drugs Strategy (2000–2004) is to ‘significantly reduce
C h a p t e r 2
(1) Problem drug use is defined as intravenous drug use (IDU) or long duration/regular use of opiates, cocaine and/or amphetamine-
type drugs. Ecstasy and cannabis are not included in this category (EMCDDA and Institute for Therapy Research, 1998).
(2) Apart from the fact that, in all CEECs, simple drug use — or possession for own use — is a crime (or a misdemeanour, in some
countries, when committed on a ‘small’ scale).
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over five years the prevalence of illicit drug use as well
as new recruitment to it, particularly among young
people under 18 years of age’.
In this respect, EU enlargement could create a new —
even if not totally unknown — situation, as drug users
differ significantly between Member States and candidate
countries. Whereas the general trend in problem drug use
in the EU is stable and the population of problem drug
users is ageing (especially users of opiates), the majority
of candidate countries are still situated in the rising part of
the curve and problem drug users are younger, on
average. 
Heroin, which is generally perceived as the most
dangerous and most harmful illicit drug, together with
other opiates, is the prevailing drug for problem drug
users in almost all candidate CEECs. The only excep-
tion is the Czech Republic, where the traditional
domestic metamphetamine (amphetamine-type drug)
— pervitin — still plays a major role. However, even
there, all the relevant indicators since 1997/8 show that
pervitin use is on the decrease and heroin use is
increasing. This heroin trend is common to all the
candidate countries — together with the abovemen-
tioned young age of drug users, who are more likely to
engage in risky behaviours such as needle sharing,
excessive polydrug use, etc., than the experienced ones
— and could create substantial risks for the future if not
properly responded to. There is also a substantial risk
that pervitin, the production of which can no longer
meet demand, will increasingly be exported from the
Czech Republic by organised crime.
Apart from the Czech Republic, ATD abuse (injecting and
non-injecting) is also present, to a lesser extent (5–10 % of
problem drug users seeking treatment), in Slovakia,
Hungary, Latvia, Lithuania and Estonia. Intravenous use of
amphetamines is marginal in Poland. 
The use of cocaine is insignificant in candidate countries,
even though there are early signs of an increase in supply,
especially in Bulgaria and, to a lesser extent, in central
Europe. 
Solvent abuse — which is not usually included in the
definition of problem drug use, even though it can
cause serious health damage — represents a challenge
for most of the candidate countries. Quantitative data
generally fails to provide a reliable picture of the
phenomenon, because the affected population is mostly
extremely young, socially marginalised and, conse-
quently, hidden. Also, the treatment facilities and
services have not succeeded in reaching the population
at risk. Qualitative data, however, suggest that solvent
abuse is a significant risk in the candidate countries,
especially among marginalised populations such as
ethnic minorities.
Treatment responses
The need for appropriate and effective responses is present
in all CEECs, but these have to be carefully targeted,
especially when the limited resources available in the
candidate countries are taken into account.
It is clear that knowledge about the target population,
its size and characteristics, and about the harms it is
suffering and that it is inflicting on society (see ‘socio-
demography’ and ‘drug indicators’ in Figure 2), is
essential when planning appropriate interventions and
treatment. Without knowing the size and extent of the
target group, it is not possible to ascertain the impact of
any treatment or repressive measure, or change of any
other kind. This underlines the importance of accumu-
lating relevant data on problem drug use in order to
influence planning for treatment and other responses.
It is obviously not possible to bring about a decrease in
problem drug use simply by applying primary prevention
measures (i.e. targeted at the non-using population).
Offering treatment, in the broad sense (3), is the only way
that this can be achieved.
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Source: 2001 CEEC national reports.
Figure 1: Drug use in the general population aged 15–64 in the Czech
Republic
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It is imperative to improve, substantially and without delay,
information gathering on treatment in the candidate
countries. Even though in some countries — such as
Slovenia — treatment modalities for problem drug use have
been put in place without proper monitoring and seem to
be appropriate in terms of needs matching and goals, it is
still necessary to assess the current situation, when planning
future responses. However, this is far from being the case in
the majority of candidate countries. 
Psychiatric hospitals have traditionally offered specialised
treatment for substance-abuse disorders, and this situation
persists in all the candidate countries. Out-patient treatment
is provided by all CEEC public health medical institutions.
However, the role of non-governmental organisations —
which are better positioned to react quickly to changes in
the drug field — differs quite substantially from country to
country. The Czech Republic, Hungary, Poland and
Slovenia seem to be the most advanced in this regard.
There are also considerable differences between countries
as regards the offer of low-threshold services (4) and their
acceptance by the public health system. International
sponsors, both public such as the EU Phare Programme and
United Nations programmes and private (where the Open
Society Institute foundations network has been a major
player), have played a crucial role in introducing this type of
service. The majority of low-threshold services are provided
by NGOs in all candidate countries. However, whereas in
the Czech Republic, Slovenia, Poland and Hungary the
government and public health authorities recognise the
importance of such facilities for public health (5) and have
provided resources for them (which also greatly facilitates
the introduction of relevant monitoring in this area), in other
countries these services still depend almost exclusively on
international support. Paradoxically, representative studies
(Csémy and Elekes, 2001) have shown that barriers exist to
the development of non-governmental facilities in Poland,
despite the fact that it was the first candidate country where
NGOs were able to develop, at a time when it was impossi-
ble in other (ex-)communist countries.
Substitution treatment — usually with methadone or, to a
lesser degree, buprenorphine — is provided for opiate users
in all candidate countries, although this varies considerably
from country to country. Such treatment is least developed
in Estonia, where administrative regulations prevented facil-
ities from fulfilling the unrealistic criteria set by government
authorities. As a result, treatment was not made available
until April 2002. Slovenia, on the other hand, represents an
example of good practice, with nationwide availability of
treatment. Again, the support of public and private interna-
tional sponsors has contributed considerably to the intro-
duction and development of this (extremely successful, in
terms of treatment goals) model.
Problem drug use estimates
Data quality
The quality of data estimating problem use prevalence is
poor in most candidate countries. Only two countries (the
Czech Republic and Poland) provide estimates based on
statistical procedures. Estimates from Bulgaria and Latvia
are based on a combination of rough multiple calculation
methods, surveys and snowball sampling. Data from Malta
are based on general population surveys, a method which
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Source: Palm and Zábransky´, 2001.
Figure 2: Planning interventions as a process of diagnosis 
(3) The term ‘treatment’ is used to define the process that begins when psychoactive substance users come into contact with a health
provider or other community service. Treatment may continue through a succession of specific interventions until the highest attain-
able level of health and well-being is reached (WHO et al., 2000).
(4) Low-threshold services provide treatment whose aim is not solely abstinence and which does not require clients/patients to be drug-
free before entering a programme. Low-threshold services target the physical well-being of the user and employ a wide range of
measures to achieve this — from nutritional and vitamin help, to needle exchange, to education about safer patterns of drug use.
(5) In some exceptional cases, some relevant services — such as needle exchange — are even provided by public health institutions in
these countries.
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fails to target the relevant groups and thus tends to under-
estimate (Hartnoll, 2002). Estimates of prevalence in
Estonia and Slovenia are based on expert opinions,
whereas Slovakia, Romania, Hungary and Lithuania still
do not have any estimates available (see Figure 3).
Generally, the capture–recapture and multivariate indica-
tors methods seem to be a good base for reliable estimates
of problem drug use at national level, preferably in
combination with other methods. Access to relevant law-
enforcement (especially police) data is of vital importance
for estimating prevalence (6). Without this data, estimates
can be too general and, therefore, of little use (7). 
Data available
Even though the methodology and data quality on
problem drug use are extremely heterogeneous, Figure 4
gives an overview of the estimated prevalence of problem
drug use in seven candidate countries (in the age category
15–64).
Problem drug use can be estimated as rather high in the
Baltic states (above 1 % of inhabitants aged 15–64),
whereas, in Bulgaria, the Czech Republic, Malta and
Slovenia, prevalence equates with the average EU level of
+/– 0.5 % (Hartnoll, 2002). Estimates in Poland, based on
the results of an isolated study in 1996/7 which is rather
old and thus with limited reliability, show relatively low
prevalence (around 0.25 %).
Regional differences within countries
Cumulative national estimates fail to show the degree of
problem drug use at local level, where communities have to
struggle directly with all its negative social consequences.
The cluster analysis of local severity of problem drug use,
Source: 2001 CEEC national reports.
Figure 4: Problem drug use (PDU) estimates in seven candidate countries
for 100 000 inhabitants aged 15–64
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Source: 2001 CEEC national reports.
Figure 3: Availability of estimates of problem drug use prevalence in
candidate countries
(6) Since the reliability of an estimate greatly depends on the mutual independence of data sources — and police data are in no way
connected to treatment data (e.g. drug-related deaths or infectious diseases, etc.), which is usually used for such estimates.
(7) In the EU, estimates of this type regularly draw on police data, while fulfilling the criteria of relevant personal data protection regula-
tions.
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developed within the framework of the EC research project
‘Copernicus’ (Palm and Zábransky´, 2001), clearly demon-
strates the different local burdens within one country (see
Figure 5). The regions with higher levels of problem drug
use (where clustering was provided according to nine differ-
ent indicators describing problem drug use) coincide, to a
large extent, with regions with higher levels of known social
problems. Such data are particularly relevant for planning
specifically targeted interventions.
Also, data gathering at local level is often more devel-
oped and more reliable in some CEECs (and Member
States), compared to nationwide methods (as demon-
strated, below, in the Multi-city study).
Problem drugs
Heroin and other opiates
The major problem drug in all candidate countries is
heroin. Although this substance seems to be
somewhat out of fashion in EU Member States, it has
found new markets in the candidate countries. It has
overtaken the vast majority of existing markets (e.g.
for home-made opiates such as ‘braun’ (8) in the
Czech Republic; poppy straw extracts known as
NB: Last 30 days before demanding treatment; percentage of clients. 
Figure 6: Opiates used by drug addicts demanding treatment in Warsaw
(Poland)
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Source: Mravcˇík, 2002.
Figure 5: Cluster analysis of local severity of problem drug use in the Czech Republic, 1998
(8) ‘Braun’ is a mixture of different opiates — mostly codeine, hydrocodone and hydrocodynal, where the preferred substance was
hydrocodone — prepared from prescribed and/or freely available analgesics containing codeine from the late 1970s until the early
1990s.
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‘kompot’ or ‘Polish heroin’ in Poland, ‘shirka’ or
‘himka’ in Lithuania, another poppy extract in Estonia and
Latvia etc. and created a new one, which is actively
promoted to newcomers to the drug scene. Even in
Lithuania, where the use of home-made poppy straw (often
mixed with benzodiazepines and/or antihistamines) has
been retained more than in other candidate countries, the
late 1990s saw an influx of brown heroin onto the market
— a process that occurred in Poland a few years sooner. In
Latvia during 1998/9, heroin prices fell to one tenth of its
price of previous years and the majority of poppy straw
users switched over to it.
In the Czech Republic, where pervitin (see below) has
dominated the scene since the late 1970s, a clear transition
is observed from this drug to heroin (Figure 6). Qualitative
data from local drug scenes are largely confirmed by the
‘first treatment demand’ indicator in the Czech Republic,
where a stabilisation and slow decline in pervitin-related
treatment demands in recent years is recorded (see Figure 7)
and a corresponding increase in demand for treatment for
opiate dependency. The same applies for drug mortality
rates in that country. 
Amphetamine-type drugs
Amphetamines-type drugs (ATDs) do not seem to be a
problem for southern candidate countries (Bulgaria,
Romania and Slovenia) and are only a minor one for the
Baltic states (Estonia, Latvia and Lithuania), despite there
having being a certain ‘Scandinavian’ tradition of ampheta-
mine abuse. For example, in Lithuania, an amphetamine-
type drug, ‘jeff’ (which is produced from medication
containing ephedrine) and the ephedrine powder, ‘Kristal’,
are injected with high frequency (up to 10 injections a day)
by users. Of the central European candidate countries (the
Czech Republic, Hungary, Poland and Slovakia), some
history of amphetamine use exists in Poland and also in
Slovakia and Hungary. The most widespread use of ATDs
(pervitin) is found in the Czech Republic.
Pervitin
The metamphetamine, pervitin, represents a traditional
Czech drug and the history of its abuse dates back to the
late 1970s. Its relatively easy production in primitive home
‘kitchen laboratories’ predisposed pervitin to be the drug of
choice in the Czech Republic. Furthermore, a number of
freely available and/or prescribed drugs (containing
ephedrine, pseudoephedrine, etc.) can be used for its
production. Nevertheless, despite a number of police
measures, the leak of ephedrine from its Czech industrial
producer (9) still represents a major source of this substance
for domestic pervitin production. This drug is also made
(under the name ‘ephedrone’) in the Baltic states.
Pervitin was the prevailing problem drug on the Czech
drug scene until the second half of the 1990s, but it is
now increasingly in competition with heroin — a process
which has paradoxically been accelerated by the current
effectiveness of the police in closing down ‘kitchen
laboratories’ (where pervitin is prepared for small,
horizontally organised groups of users, who gather
around the ‘cooker’). Even short-term gaps in markets
have invariably been quickly filled by vertically organ-
ised groups of heroin dealers — a chain where the
production stage is beyond the reach of the national
police (Miovsky´ and Zábransky´, 2001).
Parallel to this development, the prevailing home-based
‘kitchen’ production of pervitin started to be increasingly
controlled by criminal networks (mainly Russian-speaking)
who were striving to take over the market in 1999 and 2000,
according to police reports (Národní protidrogová centrála,
2000). Some qualitative data also support this hypothesis.
Theories about the progressive appropriation of closed
pervitin markets (as a result of police actions) by organised
crime is further supported by reports from the biggest
specialised treatment facility in Slovakia of a steady
increase in domestic pervitin users, never experienced even
at the time of the Czecho–Slovak Federation (Okruhlica,
2002: personal communication), and from outreach
workers in Bayern and Upper Austria (Haas, Austrian focal
point, 2002: personal communication), where a ‘new’drug
appeared under the name of ‘Fliegersalz’— by all accounts,
pervitin again.
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(9) ICN Corporation, based in Roztoky u Prahy.
Source: 2001 CEEC national reports.
Figure 7: Opiate (heroin-related) and stimulant (pervitin-related) first treat-
ment demand in the Czech Republic 1996–2001
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This information suggests that, parallel to the gradual
change occurring in the Czech drug scene, where heroin is
increasingly playing a significant role, the organised crime
network which has been gradually taking control of pervitin
production has now started to look for new markets for
pervitin abroad.
Cocaine
Cocaine abuse is relatively marginal in all candidate
countries. Its high price and short-term effect predispose it
to be a fairly rare drug, used mostly by ‘high society’.
Nevertheless, isolated evidence from Bulgaria, the Czech
Republic and Slovakia of a decrease in cocaine prices and
its sporadic appearance on the street markets, as well as a
slight increase in cocaine-related treatment demand, could
indicate a possible slow onset of this drug in central and
southern candidate countries, replaying a scenario of the
not-too-distant past in Germany, Spain and some other EU
Member States.
NB: Romania describes solvent use as ‘insignificant’ and Malta does not mention it at all.
Source: 2001 CEEC national reports.
Figure 8: Solvent-related first treatment demand in candidate countries
Solvents
Solvent abuse (inhaling) is not included in the EMCDDA
definition of ‘problem drug use’, even though the
harmful consequences of its use progress more rapidly
and are more devastating and prolonged than with any
other illicit drug, including heroin. The neurotoxic
effects are extremely debilitating and the somatic conse-
quences are profound: skin and mucosis damage, and
lung, liver and kidney disorders, together with a
markedly higher probability of various cancers for
longer-term solvent users.
According to quantitative treatment data, it could
appear as if solvent abuse is only a minor problem
and is in decline in the candidate countries (see
Figure 8). However, qualitative data suggest that there
is a substantial amount of solvent abuse, especially in
marginalised groups (Hicˇárová-Rajniaková, 2002).
This is particularly true in Slovakia, as is partially
reflected in treatment data (see Figure 9). 
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Figure 9: Patients treated for dependence on heroin or inhalants in Slovakia (1992–2001)
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year, whether for the first time or not (‘all demands’ or
‘treatment demands’).
First treatment demand: quantitative data
As with problem drug use, information about treatment
demand differs substantially — in both quality and cover-
age — between countries. In the Czech Republic and
Hungary, the information gathered covered the whole of the
country, both geographically and in terms of different types
of facilities/treatment and services. Some difficulties
emerged regarding definitions, especially in Hungary, but
these were solved in 2001. Data obtained from Slovakia,
Malta, Estonia and Lithuania cover public health/state treat-
ment facilities but fail to adequately cover NGOs and/or
low-threshold facilities. Slovenia covers out-patient facili-
ties nationwide (no matter what the status or service/treat-
ment) but none of the in-patient clinics and hospitals.
Bulgaria covers all types of facilities (although a lack of
NGOs and low-threshold facilities should be mentioned)
but only in the capital city, Sofia. A similar situation exists in
Poland, which covers a few major cities together with the
capital, Warsaw, but fails to gather data nationwide. An
overview of this situation — i.e. first treatment demand
relative to population in the CEECs — is shown in Figure 10.
However, all the limitations mentioned above should be
kept in mind when interpreting the data.
Due to incompatibility of data, it is impossible to make any
comparison between countries. It is only possible to show
trends. However, interpretation of these trends is also diffi-
cult. Since the first treatment indicator is influenced by (a)
the number of drug users in the country and (b) accessibil-
ity and matching of needs of users by services/treatment (10)
and we have no means of quantifying the impact of these
particular influences separately, any verdict of ‘worse’ or
‘better’ is fairly impossible. 
Treatment demand: quantitative data
What has been said above about first treatment demand
holds true for treatment demand. Whereas data in Hungary
covers all types of treatment, in 2000 its classification
system was not consistent with the standard EMCDDA
definitions. In 1994, Slovakia launched a monitoring system
covering the whole country using the former Pompidou
Group protocol. The protocol was changed in 2000 to meet
EMCDDA requirements. Still there are some gaps in the
coverage of the low-threshold facilities run by non-profit
NGOs. The all-treatment demand indicator in the Czech
Republic was not obtained by standard monitoring, but by
calculating an extension of the ratio between treatment
demand and first treatment demand obtained from repre-
sentative samples of different types of facilities (Mravcˇík and
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Source: 2001 CEEC national reports.
Figure 10: First treatment demand relative to population in some CEECs
Romanian data do not provide evidence of this
phenomenon — despite the existence of numerous
marginalised, homeless people seeking shelter in the
underground of the capital city, Bucharest. This
hidden population, which abuses solvents in great
amounts, was extensively covered by the world media
in the late 1990s (e.g. Sˇibík and Hruby´, 1999) and the
problem attracted the attention of researchers in the
first half of the 1990s (Hedrich and Ives, 1994).
Possible reasons for the above-mentioned discrepancy
between qualitative and quantitative data could
include the fact that solvent abuse usually occurs at a
fairly young age. This, together with the often margin-
alised status of abusers, prevents them from asking for
help from services which are not geared to their
specific situation and needs. The very low price and
licit status of industrial solvents make these
psychotropic substances readily available even to a
very poor population. Similarly, the legal status of such
substances prevents any police action, which would
otherwise constitute a valuable source of quantitative
information. Clearly, more qualitative research focusing
on volatile substances is needed in all candidate
countries.
Treatment as a response 
to problem drug use
The quantitative data collected on treatment demand cover
two categories of clients: those who enter into treatment for
the first time in their life (recorded as ‘first demand for treat-
ment’, and all those who entered treatment during a given
(10) However, (a) could be seen as a negative phenomenon, whereas (b) is undoubtedly positive.
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Zábransky´, 2001). Poland’s indicator has a long tradition
and has been considerably improved, but overlaps
between the two different systems (one for in-patient
treatment facilities, another for out-patient) have not yet
been fully addressed, even if they are rather insignificant
(according to the national report). Romania only reports
on hospital cases and Bulgaria’s current system is limited
to the capital city, Sofia. It would be possible (11) to calcu-
late the first treatment/all treatment ratio (see Figure 11),
thus showing the level of ‘stabilisation’ of client influx:
the higher the ratio, the bigger the influx of new clients
experienced by the facilities and services. However, the
ratio could only be interpreted for each country, and,
even if the strikingly high level of treatment demand
experienced in 2000 in Estonia could be read as an
indication that the treatment facilities succeeded in
attracting more users than ever before (12), this theory is
hampered by the fact that there is no method for eliminat-
ing duplication in the current system, which means that
the real number of first treatment (and treatment) may
only be a half of that calculated, or even less, because of
‘travelling’ patients migrating from one facility to another. 
On the other hand, the extraordinarily high and still
increasing influx of new patients in the Polish capital
city, Warsaw, which is covered by a stable city monitor-
ing system (see Figure 12), signifies recent major
changes in the scene, in particular a sharp increase in
the numbers of users — an indicator consistent with
qualitative information on heroin onset in the Polish
drug scene in the middle 1990s. 
Psychiatric hospitals
The candidate CEECs are post-totalitarian countries where
the former treatment system was dominated by specialised
psychiatrists — ‘alcohologists/narcologists’ — who were
responsible for substance-abuse treatment in certain
geographical areas (districts). Only Poland, with its long
tradition of treatment communities, represents a marked
exception to this rule. The overwhelming majority of physi-
cians in psychiatric hospitals were of a strictly bio-medical
orientation — an approach fostered by the former political
system and its institutions, including the ones that provided
treatment, mainly focusing on repression and provision of
compulsory treatment to drug users. 
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Source: 2001 CEEC national reports.
Figure 12: Number of clients in first and all treatment demands in
Warsaw (Poland), 1995–2000
(11) Since both nominator and denominator were obtained by the same or compatible methodology in each particular country where
data are available.
(12) It is not clear if double counting is adequately controlled.
Source: 2001 CEEC national reports.
Figure 11: First treatment demand in 2000 relative to all treatment
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This approach had no capacity to attract users in need of
treatment, on the contrary, it was seen as repressive, and the
target group generally tried to give such treatment a wide
berth. Compulsory treatment as such is no longer applied in
the candidate countries. 
Treatment as an alternative to prison exists as an option in
cases where the judge decides it is more beneficial for
society to treat the perpetrator than imprison him/her.
However, this is rarely used, with the exception of Hungary,
where 814 of such diversions were ordered in 2000,
compared for example to 95 in the Czech Republic, a
country with a similar population.
Regarding voluntary treatment and services for drug users,
large differences exist between candidate countries in treat-
ment responses and the status of providers. The most
marked common characteristic (13) is still the network of
inpatient-treatment facilities (mostly in psychiatric hospitals)
that was retained or slightly modified from the former
system. These clinics, which are oriented towards
substance abuse disorders, experienced a rapid change in
the characteristics of their clients throughout the candidate
countries. Whereas alcohol-related disorders had played by
far the major role in the first half of the 1990s, in 2000 the
situation was substantially changed everywhere, with a
stable number of admissions for alcohol-related disorders
and an increasing amount for treatment of illicit substance
abuse. Clearly this trend is still on the increase, even though
with different dynamics (see Figure 13). 
This change in patient characteristics (lower age, different
risk behaviour, more involvement in other deviant activities,
different social network, etc.) has been extremely demand-
ing on the staff. An escalating workload for expensive
psychiatric institutions also represents an increasing burden
for public health resources.
Out-patient facilities
The importance of ambulatory treatment was increas-
ingly recognised in CEECs during the 1990s, and the
ratio between in-patient and out-patient treatment has
tended towards the latter.
Ambulatory (out-patient) treatment is provided in all
candidate countries by the public health system, usually
by utilising a (sometimes reduced) network of public
health ambulatories. In some countries, newly estab-
lished private psychiatric ambulatories play an important
role. Nevertheless, these non-specialised facilities and
services handle only a minority of out-patients, whereas
specialised (increasingly non-governmental, non-profit-
making) outpatient services are responsible for the
majority of patients, in all countries except one, as
evidenced by the national focal point in Latvia. 
Therapeutic communities
In the central European countries (the Czech Republic,
Hungary, Poland and, to a lesser extent, Slovakia),
according to available data, therapeutic communities
have had satisfactory results in achieving the goal of
rehabilitation and prolonged abstinence from illicit
drugs. Nevertheless, the demand for this treatment has
obviously reached saturation point in the abovemen-
tioned countries.
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NB: One patient could be hospitalised more than once in the relevant year.
Source: 2001 CEEC national reports.
Figure 13: Illicit drug and alcohol hospitalisations in psychiatric institutions in the Czech Republic and Estonia, during 1994–2000
(13) With the exception of Poland, where a long-term tradition of therapeutic community therapy exists in the treatment of substance-
related disorders.
Poland is the country with the longest tradition in this type
of treatment. A specific model of treatment services (often
church-based) was established there in the middle of the
1980s. The role of these treatment communities in Poland
has superseded the otherwise hegemonic position of
psychiatric institutions since then.
Substitution treatment
Agonist opiate treatment is available to some degree in all
countries. Estonia is the least developed in substitution
treatment. In fact, methadone substitution has only been
officially permissible since 1998, regulated by the Minister
of Social Affairs’ Decree on detoxification and substitution
treatment of drug addicts in each health care phase of 18
March 1998 (No 20). However, the regulation’s require-
ments were extremely high — higher than for other types of
treatment — and none of the treatment facilities have been
able to meet them. In April 2002, that regulation was
abolished and a new one is now in preparation. One NGO
and one state hospital decided not to wait for the new
regulation and started to provide treatment anyway, but
finance and organisational issues are very problematic. Six
patients were receiving treatment in Estonia in June 2002.
Slovenia is the only candidate country which offers
adequate agonist opiate treatment. A countrywide network
of specialised centres — Centres for Prevention of Drugs
and the Treatment of Drug Addicts (CPTDAs) — was
approved by the Slovenian government in 1995. These
centres provide a broad spectrum of services (counselling,
individual, group and family therapy, preparation for hospi-
tal treatment, somatic care, etc.). Methadone is dispensed
by out-patient clinics or pharmacies; these do not need to
be situated within the centres. Methadone may only be
prescribed by a doctor chosen by the patient. Such doctors
must have received the appropriate licence from a CPTDA
and have gained the necessary expertise at a training course
organised by the Ministry of Health and the Clinical
Department for Mental Health. In this way, both the required
expertise and availability of treatment are guaranteed. This
system ensures a setting which is predisposed towards
successful treatment and rehabilitation of patients, whereas
leakage of the substance to the black market is negligible.
The status of agonist opiate treatment in candidate countries
is overviewed in Table 2.
Apart from in Slovenia, there is no mechanism in place for
methadone provision outside the specialised psychiatric
centres in the other candidate countries, a situation which
results in unavailability of treatment for a substantial
number of the population who live at too great a distance
from the facilities (14). Buprenorphine was recently intro-
duced in some candidate countries in 2000 and 2001. In
contrast to methadone, there are usually no limitations in
these countries for buprenorphine prescribing (15), thus it is
only the price that is the limiting factor.
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First methadone
Methadone maintenance MMT MMT clients Buprenorphine
maintenance treatment (MMT) clients in per 100 000 (Subutex®)
Country facilities/units started 2000 inhabitants available
Bulgaria 1 1995 230 2.82 No
Czech Republic 8 1993/1997 (1) 320 3.13 Yes
Estonia 2 2001 6 (2) 0.44 No
Hungary 4 1995 112 1.12 No
Latvia 1 1996 107 4.50 No
Lithuania 4 1995 577 15.42 No
Malta 1 1987 935 257.59 (2) No (3)
Poland 9 1993 1 123 2.91 Yes
Romania 1 1998 ? 0.00 No
Slovakia 1 1998 360 6.69 Yes
Slovenia countrywide coverage 1990/1995 (4) 1 348 67.72 Yes
(1) A one-year programme was started in 1993 by an NGO but after its successful run, continuation was not allowed by the public healh authorities; in
1997 an’experimental’ programme was started in the faculty hospital in Prague and subsequently — after a Ministry of Health Order — within seven
other major cities, in 2000.
(2) Data from 2001.
(3) Treatment with the opiate antagonist Naltrexone is avaliable in Malta.
(4) One ‘experimental’ programme in 1990; in April 1995, treatment was established by governmental decree.
Table 2: Agonist opiate treatment in candidate countries in 2000
(14) In Latvia, a substantial part of the resources allocated to substitution treatment were spent on transporting patients to the dispensing
unit; in the Czech Republic, some of the centres have long waiting lists and others are not used to their full capacity, even if a high
number of users live in the surrounding villages and suburbs, due to transportation problems.
(15) This means that any medical doctor can prescribe buprenorphine, regardless of whether s/he is appropriately trained.
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With the exception of Slovenia, services offering agonist
opiate treatment are totally inadequate (16). This has
significant implications, not only for protecting users’
health, but also in terms of protecting public health and
society in general. Evaluation of this treatment world-
wide has unanimously affirmed its success in preventing
the spread of drug-related infectious diseases and
substantially decreasing the incidence of crime.
Institutional responses
The role of NGOs 
Non-governmental organisations (NGOs) operate in all
the candidate countries, but only in central Europe (the
Czech Republic, Poland, Hungary and, to a far lesser
extent, Slovakia) and Slovenia do they play a major role
in public health. In these countries, the role of NGOs is
recognised by the government and municipalities, and
these provide regular funding (with strict criteria) in
order to support the services offered by NGOs. This has
been influenced by the experiences of EU Member
States and also of the abovementioned countries, where
it has been shown that NGOs are more flexible and able
to react appropriately to an often rapidly changing situa-
tion in the drug field than government/public institu-
tions.
In the four countries mentioned here (the Czech
Republic, Poland, Hungary and Slovenia), NGOs,
which were previously almost unheard of, have become
an important sector with an impact on the whole
society. The health care systems in central European
countries underwent huge reforms during the 1990s,
with a move away from the traditional institutional
system for problem drug users. These changes included
privatisation of health care facilities, development of
private facilities, the option to choose a physician or
service provider, etc. With the return of democracy,
there was a rapid development of civil liberties and
services (Csémy and Elekes, 2001).
Analysis of the development of institutions in the field of
drug demand reduction has shown that the highest
number of new organisations in the four countries was
established between 1993 and 1996. This was followed
by structural changes and an improvement in the quality
of services offered. Understandably, the new system of
care for drug users has experienced a number of teething
problems (Csémy and Elekes, 2001).
Further development, official recognition and consolida-
tion of NGOs is still at an early stage in the other six
candidate CEECs (the Baltic states, Bulgaria, Romania and
also Slovakia to some extent).
Low-threshold services
Since there has not been a tradition of low-threshold
services in the past, they were seen as radical and innova-
tive in the 1990s. The overwhelming majority of low-
threshold services operate in the framework of NGOs in the
candidate countries. Chapter 3 provides a more detailed
overview of low-threshold services in the candidate
countries.
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Eastern Europe Western Europe
Average Average
Value Year number Trend Value Year number Trend
of cities of cities
Treatment
First treatment demand 100 14  69 7
All treatment demand 339 14  684 6 
Mean age (first treatment) * 22.4 7  27.9 5 
% < 25 yrs (first treatment) * 60.8 % 10 41.5 % 5
% females (first treatment) * 20.7 % 12 21.2 % 5
Admissions psychiatric hospitals 94 9 
Admissions general hospitals 16 4
Non-fatal emergencies 99 11  36 4
NB: Indicator values are rates per 100 000 of population in the participating cities except those marked with *.
Source: Bless et al., 2000, p. 117.
Figure 14: Comparison between trends in treatment in western and eastern Europe, 1994–1998
(16) This is when compared to the European Union, the United States and other developed countries.
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Multi-city study
In 1982, the Ministerial Conference of the Pompidou
Group, the Council of Europe established the Epidemiology
expert group to develop monitoring systems for evaluating
the nature and magnitude of the social and public health
problems created by drug abuse. From the start, the expert
group adopted a city-based approach and operates as a
multi-city network. This was based on the argument that it is
more viable to develop and pilot appropriate monitoring
systems in cities than to attempt to operate on a national
scale. The smaller scale of cities makes it easier to interpret
figures and trends. Another argument was that drug
problems were mainly concentrated in urban or metro-
politan environments at the beginning of the 1980s
(Bless et al., 2000).
Even though problem drug use has spread into rural areas
during recent years, treatment indicators only represent part
of the scope of the Multi-city study and not all candidate
countries are covered. On the other hand, the analysis of
trends provides a general overview of differences between
EU Member States and candidate countries (Figure 14).
Marginalised groups and drugs
There is general agreement that socially and economically
marginalised groups are more prone to drug use and its
more serious form — problem drug use. The former totali-
tarian regimes pretended that no social differences existed
within ‘their’ countries. Consequently, no real attempt to
socially integrate marginalised minorities was ever under-
taken. The cultural and economic repercussions of the fall
of communism hit the Roma population hardest in all post-
communist countries. 
The situation of the Russian-speaking population in the
Baltic states (with the exception of Latvia) reveals a unique
picture of a group that lost its privileged status as a govern-
ing majority and found itself in a marginalised position.
Since a substantial number of them do not have citizenship
of their particular state, they have neither health nor social
insurance and the drug services are not available to them
— especially rehabilitation and other more expensive
services. It is a paradoxical though logical result of this
situation that, according to available data, drug use rates
(especially for opiates) are substantially higher in the
Russian-speaking population than in the majority of the
rest of the population.
Last but not least, increased immigration (both legal and
illegal) to the CEECs from ex-Soviet republics (such as the
Ukraine and Russia) with an extremely high prevalence of
opiate injecting and HIV could create another major
problem if suitable and accessible services are not in place
to respond to this challenge quickly.
The Roma population
It is very difficult to assess the extent of the Roma popula-
tion in candidate countries. Latent and often visible racial
prejudice ensures that the vast majority of ethnic Roma
do not identify themselves as such in census data.
However, it is safe to say that Roma are the biggest ethnic
minority in Europe.
It is also not possible to estimate the number of Roma (or
other minority) drug users, as a patient’s ethnic or cultural
background is not registered by health care facilities,
including drug treatment and syringe-exchange
programmes. A comprehensive overview of drug use in the
Roma population is absent in all CEECs. An international
qualitative study undertaken in 1999 (Grund et al., 2000) is
the only scientific source of information available.
Problem alcohol and solvent use has a long history in the
Roma population, but, unlike the rest of the population,
illicit drug use was unknown before the ‘velvet revolu-
tions’. Hard drugs were introduced into Roma communi-
ties in candidate countries in the first half of the 1990s and
they first appeared in first treatment demand monitoring
around 1995 (Grund et al., 2000). Drug dealing presents
an opportunity to make money, a situation that cannot be
underestimated in a population with far higher rates of
unemployment than national averages everywhere.
Heroin, together with solvents, represents a major
threat to the Roma community. All the available
evidence suggests that high-risk drug use is much more
widespread in the Roma drug-using population than
with ‘gadjé’ (non-Roma) junkies (17). This fact, together
with other hazardous behaviours (involvement in
prostitution, lack of awareness of the health risks
associated with unprotected sex, etc.), presents a
substantial threat to public health in the CEECs.
In all the candidate countries, very little has been done
to set in place appropriate drug and AIDS policies for
the Roma communities. The isolation of these commu-
nities is a significant barrier to the development of
services for Roma injecting drug users (IDUs).
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(17) ‘Between Gadjé and Roma drug users [in Budapest] there is a major difference. Gadjé injecting drug users use their own needles,
but Roma injecting drug users only have one needle that goes around’ (Roma outreach worker, Budapest; quoted in Grund et al.,
2000).
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The overall participation of Roma drug users in exist-
ing drug treatment programmes is negligible, particu-
larly in high-threshold facilities such as residential
therapeutic communities. However, a notable excep-
tion is methadone maintenance programmes, which
attract many Roma heroin users in some cities (Grund
et al., 2000).
The social fabric of Roma communities is beginning to be
adversely affected, as drug addiction puts pressure on the
traditional social norms of solidarity and mutual assis-
tance. The participation of an unspecified proportion of
the Roma population in the drug economy changes the
economic balance in these communities and threatens
traditional power structures. Furthermore, it seems that
Roma leaders have failed to see the problem of drug
addiction in their community for what it is — a real
problem in its own right. Instead, they have depicted it as
just another by-product of unemployment and social
segregation (Grund et al., 2000).
All the evidence suggests that drug use among the Roma
minority represents a major challenge for both public health
and the social structures in all the candidate countries.
However, even if rare, some examples of good practice
exist, such as the Initiative for Health Foundation in Sofia
(Yankova et al., 2002) and outreach work in Slovakia’s
biggest Roma urban ghetto, Lunik (Hicˇárová-Rajniaková,
2002). The first official and coordinated (government and
non-government) horizontal initiative specifically targeting
Roma drug use occurred recently in the Czech Republic. At
least three specialised outreach services for Roma drug
users also exist there and some initiatives have been taken
to employ Roma workers in the treatment facilities. This last
practice also operates in Hungary. 
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C h a p t e r 3
Drug-related infectious diseases
Introduction
Drug-related infectious diseases (DRIDs) – HIV infec-
tion, hepatitis B and hepatitis C – are among the most
serious health consequences of injecting drug use, and
may lead to significant health care costs. Injecting drug
users (IDUs) may also act as a ‘core groups’ or pockets
of infection that pose a continuous threat of spread of
infection to the general population. 
Shared needles, syringes and other injecting equip-
ment, as well as shared water for preparation and
blood-contaminated drugs, are all vehicles of infection
between drug users. 
Sexual transmission of HIV and hepatitis B virus occurs
less frequently but, due to the relatively high preva-
lence of these infections among drug users, is still
significant. Moreover, HIV and HBV can spread by
sexual transmission to the wider population. Sexual
transmission of HCV is uncommon.
HIV infection, hepatitis C virus (HCV) and hepatitis B
virus (HBV) are viral infections with very serious or
even fatal consequences. HCV and HBV often lead to
chronic liver disease and, to a lesser extent, liver
cancer. With HCV there is a 60–80 % probability of
chronic liver disease development and 5–10 % in the
case of HBV. HCV, which is a common infection
among IDUs, can spread particularly stealthily,
because approximately 90 % of cases remain clinically
undiagnosed yet still lead to chronic disease. HIV,
HCV and HBV have high social costs through hospital-
isation, chronic illness and premature death. It is
estimated that 0.5 % of the total EU health care budget
is allocated to drug-related HIV infection, HCV and
HBV, with HIV accounting for 71 %, HCV for 24 %
and HBV for 5 % of these costs. The actual proportion
and quantity of these costs may vary according to the
prevalence of the given infection in the respective
country.
Other infections are also closely connected to drug use,
including tuberculosis (which re-emerged in recent
years due to its close association with HIV infection),
sexually transmitted diseases and hepatitis A infection
(a typical disease associated with ‘dirty hands’, which
can be connected to lack of hygiene in a drug-related
lifestyle).
One of the key public health problems arising from
drug use is the high burden that DRIDs place on the
health care system. One of the six main targets of the
EU Drugs Strategy (2000–2004) is a substantial reduc-
tion of the incidence of HIV, HCV and HBV infections.
Even though the situation regarding DRIDs is more
favourable in most of the CEECs than in EU countries,
the potential still exists for them to spread. 
Preventive measures are needed to control the trans-
mission of infections among drug users in CEECs.
Harm-reduction responses such as easy access to clean
injecting equipment, condoms, HIV testing and
counselling, outreach work and substitution treatment,
are very effective in decreasing DRIDs. Improving the
quality, accessibility and coverage of these responses
must be one of the main targets of CEECs with respect
to drugs.
Data quality and availability
Monitoring systems for DRIDs are being developed in
the CEECs, but these systems need both financial and
institutional support. Due to insufficient budgets, there
is often a precarious balance maintained between
monitoring needs and the lack of financial resources.
Most CEECs have developed HIV surveillance systems
in order to monitor the trends of HIV infection preva-
lence among IDUs. Less information is available about
the prevalence and trends of hepatitis C virus and
hepatitis B virus infection. Differences in the available
HIV/HCV/HBV prevalence data from individual
countries, as well as within these countries, must be inter-
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preted with caution. In addition to real differences in
prevalence rates, the information may reflect variations in
the methodological approach, such as the specific
characteristics of subgroups of IDUs included in preva-
lence surveys or surveillance systems and differences in
coverage, sampling and testing approaches.
All CEECs collect relatively valid information on newly
diagnosed cases of HIV infection. In many countries, it is
probable, even where data is available, that the reported
national rates for the incidence of HCV and HBV are
substantially underestimated. Despite this proviso, trend
monitoring is still useful. Reliable information on the
transmission route is often unavailable and the reporting
methods may vary greatly between countries. It is there-
fore very difficult to compare the reported incidence rates
of newly diagnosed HCV and HBV infections between
the countries. 
Data regarding tuberculosis, and other infectious diseases
among drug users, is generally lacking in CEECs and
further development of the monitoring system in this field
is needed. 
It is even more difficult to monitor and evaluate preven-
tion measures in the field of infectious diseases among
IDUs as many epidemiological, social, economic and
legal factors have brought about changes in the situation.
Nevertheless, the principal evidence based on harm-
reduction approaches is well known. The responses that
follow from these approaches have been developed to
some extent in the CEECs and, in some countries, it is
possible to find examples of good process and outcome
evaluation.
The EMCDDA has been supporting candidate countries
in order to improve the collection, analysis and dissemi-
nation of objective, reliable and comparable information
about drug-related infectious diseases and responses.
Collated information about HIV infection among IDUs
complements the information collected by the EuroHIV.
Overview of situation
Of all the CEECs, the Baltic states are the most affected by
HIV infection and viral hepatitis. Poland has serious
problems with HIV among IDUs, but the situation has
stabilised. In other countries, while HCV is at a high
level, the HIV epidemic among IDUs has remained low.
Available data on IDUs infected with HIV show varia-
tions from 0 % (Bulgaria, the Czech Republic and
Slovakia) to 40 % (Estonia). In the case of HCV,
infection rates vary between 6 % (Hungary) and 80
% (Estonia, Latvia and Lithuania). The situation in
most of the CEECs is currently more favourable
compared with EU countries, but the potential for
adverse change exists, as injecting remains preva-
lent among heroin and opiates users: 80–90 % of all
opiate users are injectors and this trend remains
stable, or is even on the increase, in most of the
CEECs. On the other hand, as heroin injection has
increased in the CEECs, the use of home-made
drugs, both opiates and stimulants (which are
associated with a higher risk of infection due to
needle and paraphernalia sharing), has decreased
recently.
The levels of response to DRIDs in CEECs vary accord-
ing to the activities of the national drug coordinating
bodies as well as other governmental and, very impor-
tantly, non-governmental organisations. The candidate
countries have established harm-reduction and other
prevention measures but improvement in the coverage
and availability of these is needed throughout the
region. 
Injecting and sexual risk behaviour
Injected drugs 
In the CEECs, heroin is now commonly injected, with
heroin users representing more than 90 % of cases
treated in Bulgaria and Slovenia. Heroin is practically
the only drug which is injected in both these countries,
as is also the case for Romania. In other countries,
especially the Baltic states and Poland, injecting of
home-made opiates still persists. However, the use of
such home-made substances has decreased in recent
years.
In the Czech Republic and, to a lesser extent, in
countries such as Slovakia, Hungary, Lithuania,
Estonia and Latvia, stimulants are also injected.
Whereas the users of home-made amphetamine–type
drug (ATDs) (pervitin) in the Czech Republic represent
more than 50 % of all newly treated injecting users
and more than 50 % of all estimated injecting users, in
the other countries ATD users represent 5–10 % of all
treated users.
The main identifiable trend across all CEECs is that,
while heroin use has increased in recent years, the use
of home-made products, both opiates and ATDs, has
decreased.
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Characteristics 
and determinants of injecting
Injecting of opiates, including heroin, is the main pattern
of use, but there is not enough data for proper cross-
country comparison. Nevertheless, several common
features are discernable (see Table 3). The rate of opiate
injection, both home-made and heroin, remains high.
Across the countries the proportion of injectors among
opiate users varies between 80 and 90 %. This trend has
remained stable for Bulgaria, Slovakia and Slovenia, but
has increased in other countries. In Bulgaria and
Slovenia, it is possible to carry out a comparison
between ‘all’ clients and ‘new’ clients demanding heroin
treatment. While the 10 % difference between ‘all’ and
‘new’ clients injecting heroin indicates a decrease in
recent heroin injection in Bulgaria (in line with EU
countries), in Slovenia, injectors represent almost 100 %
of the total number of existing and new heroin users. In
the Czech Republic, pervitin remains the most common
injected drug, even though there has been a decline in
its use. According to the first treatment demands, the
percentage of IDUs among all heroin users, is approxi-
mately 90 %, representing an increase in recent years.
The percentage of IDUs among pervitin users is approxi-
mately 80 %, a figure which has remained stable.
Poland seems to be the only country where there has
been a substantial decrease in injecting. It remains open
to question, however, whether the reporting system was
artificially influenced. Despite this concern, there is a
difference in the number of first and repeated treatment
demands, indicating that new users inject less. Smoking
of heroin has become more prevalent.
There are some factors that influence the route of
administration and lead to more high-risk patterns of
drug use. According to qualitative research in the
Czech Republic, the shift from low-risk patterns of use
(sniffing or smoking) to high-risk ones (intravenous use)
is often motivated by the search for more intense
experiences and also by developing tolerance. It is
clear that financial problems, or less availability of a
drug on the market (often due to police activity) and a
consequent rise in price, represent factors that could
increase the risk level of drug use. However, informa-
tion provided by the municipal police of Vilnius
(Lithuania) indicates that smoking of heroin from
aluminium foil was at its most widespread in 1998, a
period in which the price of heroin was falling, which
would seem to contradict this.
Sharing of needles and other paraphernalia (cookers,
filters, etc.) or sharing a prepared drug is the most
important risk factor leading to drug-related infectious
diseases. Using one container for the drug is especially
common when home-made drugs are used.
31
Country Characteristics 1996 1997 1998 1999 2000
Bulgaria
(Sofia) All treatment — IV (1) route of heroin (%) 70.2 77.6 85.4 81.6 83.3
First treatment — IV route of heroin (%) 61.3 69.1 80.7 73.3 72.1
Czech Republic First treatment — IV route of heroin (%) 67.5 74.4 78.6 87.4 89.1
First treatment — IV route of pervitin (%) 77.9 68.4 78.0 79.1 79.9
Estonia Recent injecting of any drug (%) n.a. n.a. n.a. 78.6 84.4
Hungary All treatment — IV route of heroin (%) 57.4 79.9 53.3 51.2 80.5
Daily injecting heroin users out of all heroin users in treatment (%) n.a. n.a. n.a. > 70 > 70
Latvia Injecting as pattern of first use (in FTD) (2) (%) n.a. n.a. 65.8 73.3 80.7
All treatment — IV route of heroin (%) n.a. n.a. 86.1 96.7 97.7
Lithuania Recent injecting of any drug (%) n.a. 93,4 93,2 88,8 95,0
All treatment — IV route of opiates (%) n.a. n.a. n.a. 95 n.a.
Poland
(Warsaw) IV route of all users demanding treatment — repeat contact 74.7 58.9 47.6 33.8 28.0
IV route of all users demanding treatment — first contact 24.1 20.2 11.0 12.6 9.5
Romania n.a. n.a. n.a. n.a. n.a. n.a.
Slovakia All treatment — IV route of heroin (%) 87.8 79.61 80.08 79.61 80.24
First treatment — IV route of heroin (%) n.a. 75.43 76.86 79.11 77.1
Slovenia All treatment — IV route of heroin (%) 99.7 99.7 99.7 99.8 n.a.
First treatment — IV route of heroin (%) 99.6 99.7 99.4 99.6 n.a.
n.a. = not available.
(1) Intravenous use is almost identical to injecting. A very small proportion of long-term IDUs inject subcutaneously or intramuscularly. 
(2) FDT – First treatment demand.
Table 3: Intravenous drug use in the CEECs according to different indicators
2 0 0 2  R e p o r t  o n  t h e  d r u g  s i t u a t i o n  i n  t h e  c a n d i d a t e  C E E C s
It is not possible to carry out a cross-country compari-
son of the data on high-risk behaviour. However,
provided time series are available, it is possible to
monitor behavioural changes within the particular
country.
Estonian data, for example, show an increase in both
current and previous needle sharing, even though the
existing data is incomplete. In 1999, when heroin
replaced the poppy mix in Estonia, the level of needle and
drug sharing decreased. This trend did not last long and,
by the following year, the level of needle sharing was
again on the increase. In 2000, the number of users in
treatment who had shared a needle in the previous month
had increased from 7.9 to 22.4 %, while lifetime sharing
had increased from 24.5 % in 1999 to 34 % in 2000.
Inexperienced users in the Czech Republic tend to use
drugs in a risky way, but it seems that age is a signifi-
cantly more important risk factor than the actual drug
use experience. However, it should be noted that even
clients currently in harm-reduction programmes
(including those who are experienced or older) share
needles and paraphernalia to a certain extent, despite
awareness of the risks. It appears that there is approxi-
mately a 50 % reduction in risky behaviour when a
client has spent at least one year in a treatment
programme. It is possible to grade the perception of risk
in different situations. The actual sharing of a needle is
perceived to be the most risky, while clients regard
repeated use of one syringe as markedly safer. At least
one-third of those interviewed believe that it is suffi-
cient to flush the syringe through with water. In general,
drug users seriously underestimate the health risks
associated with injecting; they often regard hepatitis as
‘normal’. Data from the year 2000 on needle sharing
among injecting users varied between 35 and 51 % of
current users (in the preceding one to three months)
and 49 and 55 % of those who had used longer ago.
Data gathered between 1998 and 2000 by the Ikterus
project in the Karvina district indicated a rate of
lifetime sharing of 91 %.
Between 20 and 27 % of Hungarian IDUs shared their
boiling pots in the last month, and 37 % of injectors
demanding treatment and 64 % of those outside of
treatment did not share their needles in the preceding
month.
Polish findings show that sharing is more frequent
among users of home-made opiates. Even though IDUs
are aware of the risks of infection, they share needles
when craving for the drug is at a high. Even users who
try to avoid sharing mention one crucial high-risk situation
— the deep stupor following opiate use — when they lose
control of their equipment. Users of home-made opiates
usually warm the liquid prior to injection in order to
avoid infection and they subsequently rinse the equip-
ment in cold water. The risk of infection is frequently
ignored and considered a ‘professional risk’. Data from
Warsaw show a decrease in the level of high-risk drug
use. Between 1995 and 1999, the percentage of clients
who had shared a needle in the 30 days preceding
treatment decreased from 31.3 to 12.8 %. This positive
trend was reversed, however, in 2000, when the
percentage of sharing IDUs increased to 16.9 %. It is
possible that this indicates the presence of a new gener-
ation of drug users who have not been reached by the
harm-reduction measures.
Sexual risk behaviour
Sexual risk behaviour also represents an important trans-
mission route for infection among drug users. Not alone
that, it also allows for the spread of infection into the
population at large. However, little data is available in the
CEECs on this issue.
Male problem drug users in Hungary, for example, admit-
ted to having sex without a condom 6–8 times in the
month prior to treatment, while for females it was 2–4
times (Rácz et al., 2002).
In the Czech Republic, 80 % of problem drug users
neither live with a partner nor have a short-term sexual
relationship. Only 11 % of users maintain a long-term
relationship (Miovsky´ et al., 2001). Approximately half
of problem drug users engage in promiscuous sexual
behaviour and prostitution is an economic fact of life for
4 % of problem users. However, in some regions,
Northern Bohemia for example, as many as one-third of
problem users are prostitutes. The data on condom use
confirms high degrees of unprotected sex, with only 20
% of problem drug users using condoms regularly and as
many as 53 % never using them at all (Bem et al., 1999).
Prevalence and trends
HIV
With regard to HIV infection among IDUs, it is possible to
distinguish three different groupings in the candidate
CEECs: 1) the three Baltic states, 2) Poland, and 3) the
remaining six countries.
The Baltic states
In the Baltic states, there is a high proportion of IDUs
among all reported HIV positive cases. A huge increase in
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Source: Adapted from European Centre for the Epidemiological
Monitoring of AIDS (2001): HIV/AIDS surveillance in Europe, mid-year
report 2001, No. 65.
Figure 15 A: Reported newly diagnosed cases of HIV infection among
IDUs per million inhabitants in the CEECs
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HIV cases was observed, particularly in Latvia, during
the 1990s and in Estonia in 2000. Newly reported HIV-
positive cases among IDUs in Estonia and Latvia
reached 254.1 and 156.3 cases per 1 million inhabi-
tants, respectively. Lithuania had a lower level of newly
infected HIV cases among IDUs: 12.7 cases per 1
million inhabitants. In 2000, the percentage of IDUs
among all reported HIV positive cases was 90.8 % in
Estonia, 81.3 % in Latvia and 72.3 % in Lithuania.
Regarding the prevalence of HIV antibodies, a massive 
41 % of IDUs who were tested in Estonia and between
8.8 and 19 % who were tested in Latvia are infected
with HIV. The most recent results from Lithuania report
1.6 % of IDUs infected with HIV. The trend of antibody
prevalence is unknown in Estonia, growing in Latvia
and decreasing somewhat in Lithuania, especially in
Vilnius (most probably due to the timely implementa-
tion of harm-reduction measures).
In 1997 and 1998, the first two cases of HIV infection
among IDUs were diagnosed in Estonia. In the year
2000 alone, 390 HIV-positive cases were diagnosed in
Estonia, 354 of them among IDUs. The age of those
infected was generally between 15 and 24 years,
although the youngest person infected was only 13
years old. A considerable proportion of the cases are
from Narva, an industrial city in north-eastern Estonia
with a mainly Russian-speaking population. The
Estonian Ministry of Social Affairs has recommended
that the situation be classed as an HIV epidemic. The
epidemic spread of HBV and HCV at the end of 1996
and the beginning of 1997 in Tallinn (some 200 cases,
90 % of them connected to IDUs) preceded this HIV
outbreak and could be considered as an indication of
the risk of HIV infection for IDUs in Estonia.
The first Lithuanian HIV-infected opiate injector was
detected in the port city of Klaipeda in 1994. Nearly all
instances of HIV in Lithuania originate from the
Klaipeda region, which is in close proximity to the
Kaliningrad district (a Russian enclave, where IDUs
represent the majority of HIV cases). An increased risk
is also posed by Belarus, another neighbouring region
with significant HIV prevalence.
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Absolute Relative incidence
Country incidence per 1 million inhabitants Trend
Bulgaria 1 0.1 
Czech Republic 4 0.4 
Estonia 354 254.1 
Hungary 1 0.1 
Latvia 379 156.3 
Lithuania 47 12.7 
Poland 330 8.5 
Romania 0 0.0 
Slovakia 0 0.0 
Slovenia 1 0.5 
Source: Adapted from European Centre for the Epidemiological
Monitoring of AIDS (2001): HIV/AIDS surveillance in Europe, mid-year
report 2001, No. 65
Figure 15 B: Reported newly diagnosed cases of HIV infection among
IDUs per million inhabitants in the CEECs (Estonia and
Latvia not shown)
Table 4: Reported newly diagnosed HIV infection cases among IDUs per
million inhabitants in 2000
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Poland
Newly reported HIV-positive cases among IDUs repre-
sented 8.5 cases per 1 million inhabitants in Poland in
2000. Poland was the earliest of all the candidate CEECs
to experience an HIV epidemic among IDUs. The
outbreak of the epidemic started among IDUs in 1989,
when 411 HIV positive IDUs were diagnosed
(compared with 12 cases the previous year). By 1991,
an annual high of 653 HIV positive cases among IDUs
was diagnosed. Since then, the incidence has decreased
and stabilised at a level of between 310 and 350 cases
of HIV positive IDUs per annum between 1995 and
2000. IDUs represent approximately 50–60 % of all
new HIV cases at present and this percentage has
remained stable.
The prevalence rate of HIV antibodies among IDUs in
2000 shows that 11–16 % of IDUs were infected with
HIV. Local data from Warsaw indicates that this preva-
lence rate is on the decrease.
Remaining countries
In Bulgaria, the Czech Republic, Hungary, Romania,
Slovakia and Slovenia, the HIV epidemic among IDUs
has remained at a low level. Newly reported HIV-
positive cases among IDUs vary between 0.0 in
Romania and Slovakia and 0.4 and 0.5 cases per 1
million inhabitants in the Czech Republic and Slovenia.
In the long term, the percentage of IDUs among all
reported HIV cases varies from 0.0 in Romania to 6.5 in
Slovenia.
The prevalence rate of HIV antibodies among IDUs has
remained low; less than 1 % of IDUs are infected with
HIV.
So far, the number of diagnosed AIDS cases among
IDUs remains low in all CEECs because of the long
latency period of HIV infection, except for Poland,
which has a stable trend, and Latvia, where it is on the
increase.
It is possible to identify groups of drug users with a
higher risk of HIV infection, such as detainees and
prisoners. One of the reasons is that these groups are
exposed to a higher risk of transmission due to the
limited access to harm-reduction measures in the
criminal justice systems in the CEECs. In Estonia, for
example, approximately 25 % of all reported HIV
cases are detainees, but this number has been decreas-
ing recently. In Latvia, approximately 30 % of all
reported HIV-positive IDUs are in prison, while in
Lithuania the figure is approximately 10 %. In May
2002, 10 % of 1 977 prisoners in one Lithuanian
prison were found to be HIV positive, most of the cases
Source: 2001 CEEC national reports.
Figure 17: Prevalence rates of HIV antibodies among IDUs in the CEECs
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Source: European Centre for the Epidemiological Monitoring of AIDS
(2001): HIV/AIDS surveillance in Europe, end-year report 2000, No. 64.
Figure 16: Percentage of IDUs in all new HIV positive cases in the CEECs
being drug-related. It is estimated that about 80 % of
all users in Polish therapy wards are HIV positive.
Ethnic minorities, apart from the Russian-speaking
inhabitants of the Baltic states (see above), are at a
greater risk of infection, due to their social isolation
and the low availability of harm-reduction measures.
Roma communities are especially endangered, despite
several targeted measures that have been implemented
in Bulgaria, the Czech Republic, Slovakia and
Lithuania.
The situation surrounding HIV infection in some
CEECs can be potentially influenced by ongoing
epidemics in neighbouring countries. For example, in
Russia, including the territories of Kaliningrad, Belarus
and the Ukraine, the spread of HIV infection is associ-
ated to a large extent with drug injection.
Viral hepatitis
There is not enough data available in order to compare
newly reported HCV and HBV infection among IDUs
in all the CEECs. Only a few countries are able to
provide this data with an acceptable degree of reliabil-
ity. However, it is known that 45–55 % of all newly
reported cases of HCV and 20–50 % of all newly
reported cases of HBV are IDUs. One has to bear in
mind that most of the new cases, particularly of HCV,
remain unreported, due to the low percentage of clini-
cally apparent cases.
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Country Population Geographical area Year/period Sample size Rate (%) Trend
Bulgaria Low-threshold centres,
treatment centres, outreach work, Sofia 2000 711 0 
syringe exchange schemes
Czech Republic n.s. Czech Republic 2000 2091 0 
Low-threshold centres Karvina 2000 123 0 
Estonia Treatment centres,
hospitals, syringe exchange schemes, Tallinn 2000 964 41 n.a.
prisons, overdose cases, emergencies
Hungary Treatment centres, outreach work Budapest 1999–2000 179 1-5 n.a.
Latvia Treatment centres, hospitals Latvia 2000 1447 9 
Outreach work Riga 2000 113 12 n.a.
Syringe exchange schemes Riga 2000 307 19 n.a.
Lithuania n.s. Lithuania 2000 772 2 6
Low-threshold centres Klaipeda 1999 278 3 6
Poland Treatment centres, STD clinics, 
hospitals, testing sites Poland 2000 3106 11 n.a.
First treatment Warsaw 2000 275 16 
Romania n.a.
Slovakia Treatment centres Bratislava
and Kosice 2000 801 0 
Slovenia Treatment centres Slovenia 2000 484 0 
Treatment centres Ljublana and Koper 2000 147 1 n.a.
n.a. = not available.   n.s. = not specified.
Table 5: Prevalence of HIV antibodies among IDUs in the CEECs
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NB: A more representative prevalence rate of 20 % for the low-threshold
centres was used for the Czech Republic.
Figure 18: Prevalence rates of HCV antibodies among IDUs in the CEECs
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The prevalence rates of HCV and HBV antibodies
provide a more reliable picture (and one which bears
comparison) within the CEECs (see Tables 6 and 7).
However, the figures vary, both between and within
countries, in relation to the year of the study, the
country, the sample of tested IDUs , the average
duration of injecting and the risk level of injecting. A
comparison of the HCV prevalence within individual
countries is very similar to the comparison of HIV
infection. Latvia, with 83 % of IDUs infected with HCV,
and Estonia, with 82.5 %, represent the most affected
countries. Hungary, with 6 %, has the lowest reported
country level.
The incidence rate of HCV antibodies has been
calculated in two CEECs in order to estimate the
speed of HCV dissemination. In Bratislava (Slovakia),
13 cases per 100 persons per year among retested
negative IDUs were infected with HCV. In the
Karvina district (Czech Republic), the figure was 18.4
cases per 100 people per year between 1998 and
2000, while the trend during that period showed a
decrease.
Except for some countries and some samples of long-
term users, the prevalence rate of HBV antibodies is
two to three times lower than for HCV.
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Country Population Geographical area Year/period Sample size Rate (%) Trend
Bulgaria Low-threshold centres,
treatment centres, outreach work, Sofia 2000 711 75 (1) 
syringe exchange schemes
Czech Republic Low-threshold centres Karvina 2000 90 9 
Methadone treatment Prague 1999 60 46 n.a.
Estonia n.s. Tallinn 1994–1995 57 79 n.s.
Hungary Treatment centres, outreach work Budapest 1999-2000 141 5 n.a.
Latvia Methadone treatment Riga 1997 194 38 n.a.
Lithuania n.s. Lithuania 2000 698 7 
Poland n.a. n.a. n.a. n.a. n.a. n.a.
Romania n.a. n.a. n.a. n.a. n.a. n.a.
Slovakia First treatment Bratislava 2000 n.s. 7 
Slovenia Treatment centres, hospitals Slovenia 2000 472 5 
(1) Bulgaria has reported a 5 % prevalence of HBsAg, which indicates approximately 75 % of IDUs infected with HBV.
n.s. = not specified.
n.a. = not available.
Table 7: Prevalence rates of HBV antibodies among IDUs in the CEECs
n.s. = not specified.
n.a. = not available.
Table 6: Prevalence of HCV antibodies among IDUs in the CEECs (specimen = serum, marker = HCV Ab)
Country Population Geographical area Year/period Sample size Rate (%) Trend 
Bulgaria Low-threshold centres,
treatment centres, outreach work, Sofia 2000 673 72 
syringe exchange schemes
Czech Republic Low-threshold centres Karvina 2000 91 20 
Methadone treatment Prague 1999 60 68 n.a.
Estonia n.s. Tallinn 1994–1995 57 83 n.a.
Hungary Treatment centres, outreach work Budapest 1999–2000 141 6 n.a.
Latvia Methadone treatment Riga 1997 161 83 n.a.
Lithuania n.s. Lithuania 2000 693 79 
Poland n.a. n.a. n.a. n.a. n.a. n.a.
Romania n.a. n.a. n.a. n.a. n.a. n.a.
Slovakia First treatment Bratislava 2000 n.a. 34 
Slovenia Treatment centres, hospitals Slovenia 2000 475 21 
Responses
The basic measures employed to reduce negative health
consequences and the social costs of high-risk behav-
iour among drug users include access to clean injecting
equipment, substitution treatment (see ‘Problem drug
use and treatment responses’), reaching out to injecting
drug users, counselling and testing, access to condoms
and provision of appropriate information. These
measures are referred to as ‘harm reduction’. Most of
them were introduced and further developed as a
response to the spread of HIV infection among drug
users in the 1980s. Harm-reduction measures are imple-
mented in all the CEECs nowadays, but their range and
coverage needs to be improved on.
In recent years, some new harm-reduction approaches,
such as medically supervised injecting rooms and
controlled heroin distribution, have been applied in
some European countries and in the United States. As
yet, none of these innovative approaches have been
implemented in the CEECs.
Access to clean injecting equipment
In all of the CEECs, needle and syringe exchange
programmes (SEPs) have been implemented. The cover-
age rate per country varies. Needle exchange is avail-
able in the capital city or several main cities for
Bulgaria, Hungary, Latvia, Lithuania, Slovenia, Slovakia
and only in the capital of Romania. Estonia has
exchange programmes in nine cities and Poland in 15
municipal areas. Syringe and needle exchange were
available in 66 out of 78 districts in the Czech Republic
in 2000. Rural regions are rarely covered by the syringe
exchange programmes (see Table 8).
In countries which have available data, the number of
syringes distributed per year varies from 40 000 in
Estonia to over 1 million in the Czech Republic. Even
though the syringe exchange programmes are not
widely available in most countries, the ratio of
exchanged needles and syringes to number of inhabi-
tants of a country is an appropriate comparison
technique (see Table 8). Hungary reports the lowest
number of needles and syringes distributed in 2000: 57
units per 10 000 inhabitants. The Czech Republic
achieved the highest level: 1 120 needles and syringes
distributed per 10 000 inhabitants. With the exception
of Poland, the prevalence of DRIDs seems to be related
to the timeliness of implementation of SEPs, probably
indicating early social awareness of the potential threat
to public health. Despite Poland being the first of the
CEECs to implement SEPs in 1988, the HIV epidemic
among IDUs was not avoided. A possible explanation
could be that the availability and coverage of the SEPs
in the 1980s and the early 1990s was not sufficient.
There is limited data about the proportion of IDUs
involved in the syringe exchange programmes. What is
clear is that this needs to be increased in all CEECs. In
Estonia, about 10 % of all IDUs are thought to be
involved in exchange programmes. In the Czech
Republic, approximately 50–60 % of the syringes used
by the IDUs per year are distributed within the frame-
work of syringe exchange programmes.
Non-governmental organisations (NGOs) administer
most of the syringe exchange programmes in each
country. Nowadays, in all countries with available
data, needles and syringes are distributed freely
without the rigorous application of a ‘one for one’
exchange. The syringe exchange is often carried out
within the framework of outreach work or by use of
mobile units. This mobile exchange is usually carried
out in places where illicit dealing already takes place.
No needle and syringe exchange programmes operate
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Source: 2001 CEEC national reports.
Figure 19: Syringes distributed in syringe exchange programmes per      
10 000 inhabitants in the CEECs in 2000
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in prisons or detention units, even in the countries
with a high HIV prevalence among prisoners who
inject drugs.
Two stumbling-blocks preventing the achievement of a
higher volume of distributed syringes were the scarcity
of organisations implementing syringe exchange
programmes and the lack of financial resources. Other
reasons for this failure include the following: special
permission for syringe exchange is required from the
national authorities (Hungary), police have been
reported disturbing clients near exchange points
(Estonia) and IDUs can be afraid to exchange needles
due to fear of stigmatisation (the Czech Republic).
In all of the CEECs with available data, it is legal for pharma-
cies to sell syringes and needles. Staff attitudes in the
pharmacies vary between countries, with Estonia reporting
a rather negative attitude towards IDUs, and Slovenia
reporting a fairly positive one. In Slovenia, in the cities of
Celje and Zalec, two pharmacies are involved in syringe
exchange. The results of a questionnaire carried out in
pharmacies in the Czech Republic in 1998 and 2000 show
that 38 to 43 % of the staff demonstrated a negative attitude
towards the sale of injection materials to drug users. 
In most countries, it is impossible to estimate the number of
syringes sold by pharmacies. In the Czech Republic,
approximately 900 000 syringes have been sold annually in
recent years, less than half of all syringes used by IDUs.
The price of an injecting set varies from 0.05 to 0.15 in
the CEECs.
Estonia was the only country where an educational
programme and staff training for pharmacies was
carried out.
Distribution of condoms 
Condoms are generally available in stores, shops,
pharmacies and petrol stations in all CEECs. Free
distribution is provided by syringe exchange
programmes, outreach services and low-threshold
centres for prostitutes and IDUs, depending on the
available financial resources of the given institution. In
some countries, condoms are available in prisons. For
example, in some Estonian prisons, they are distrib-
uted in meeting rooms and are available for relatives
of the inmates. In Slovenia, condoms are freely avail-
able in prisons. Condom distribution for prisoners is
prohibited in Bulgaria.
Availability of HIV testing
Availability of HIV tests varies both between and
within countries. In Bulgaria, Estonia and Slovenia,
HIV testing is only available in a few centres. In other
countries, HIV testing is provided by the institutional
network that covers the whole country (county hospi-
tals in Hungary, public health institutions in the Czech
Republic and Slovakia). In all countries with available
data, testing is anonymous and free. In Lithuania, a
Ministry of Health decree obliges HIV testing of known
IDUs to be carried out once or twice a year.
HIV/AIDS therapy
In all countries with available data, HIV/AIDS therapy
is free and is either covered by insurance or paid for
from specific budgets. In many countries there is no
difficulty about provision of treatment to IDUs. In
Estonia, only drug-free patients are eligible for anti-
retroviral treatment.
Vaccination 
With regard to HIV, HCV and HBV infections, HBV is
the only one for which a vaccine is produced and
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Country SEP coverage Number of SEPs Syringes distributed Per 10 000 inhabitants Year of implementation
Bulgaria 4 cities 6 200 000 252 1995
Czech Republic Almost the whole country 66 1 150 000 1 120 1993
Estonia 9 cities 9 20 500 147 1997
Hungary 4 cities 4 57 000 57 1995
Latvia 3 cities 1 52 000 215 1999
Lithuania 5 cities 5 33 000 (1) 89 1996
Poland 15 cities 15 469 000 122 1988
Romania The capital n.a. n.a. n.a. n.a.
Slovakia The capital 3 100 000 185 1994
Slovenia 3 cities 3 160 000 805 1992
NB: n.a. = data not available.
(1) Data from the Klaipeda syringe exchange programme in 1997.
Table 8: Needle and syringe exchange programmes (SEPs) in the CEECs in 2000
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used. In most of the countries, HBV vaccination for
IDUs is paid for just as it would be if a ‘regular’ appli-
cant applied for it. In Slovenia, HBV vaccination is
covered by insurance and almost all IDUs in treatment
are vaccinated free of charge, but the vaccination
scheme is encountering some problems. In other
countries, only single cases or limited groups of IDUs
are vaccinated. In the Czech Republic, an extensive
vaccination campaign was conducted among IDUs in
1998 and 1999, when almost 1 000 users were vacci-
nated against HBV. In the Karvina district of the Czech
Republic, vaccination against HBV is provided
through a special project supported by the Ministry of
Health and there is approximately an 80 % take-up
rate for the scheme. In Bratislava (Slovakia), when
vaccination against HBV was provided, more than 1
000 clients received all three doses of the basic
scheme.
Evaluation of harm-reduction measures
Even though it is very difficult to prove any direct
causal relationship between preventive measures
focused on IDUs and real changes in their health status
or risk profile, mention of a few examples will demon-
strate the outcome evaluation of preventive responses.
Evaluation of the Sofia Needle Exchange Project in
Bulgaria showed a positive benefit for the project’s
participants. There was a decrease in the sharing of
injecting equipment and in unsafe sexual practices,
while the knowledge of risks and the demand for, and
use of, condoms increased.
The Ikterus project, controlled by the District Institute
of Public Health in Karvina (the Czech Republic),
operates through very close cooperation between the
institute and four low-threshold centres in the district.
The project, which started in 1998, consists of testing,
vaccination, syringe exchange and information
dissemination. Two HBV infection outbreaks, mostly
among IDUs and their sexual partners were controlled
by vaccination of contact persons in the locus of the
epidemic. In the Karvina district, the incidence rate
and seroprevalence of HCV has decreased in recent
years, while HIV remains at zero level.
The drop-in centre in Klaipeda (Lithuania) provides
needle, syringe and condom distribution plus
counselling and information dissemination. Their data
indicates a decrease in HIV prevalence among IDUs
from 6.8 % in 1997 to 2.9 % in 1999. This positive
trend was corroborated by testing undertaken by the
Counselling Clinic for Social Diseases, ‘Demetra’, of
the Lithuanian AIDS Centre, which found that approxi-
mately 1.5 % of drug users are infected; this percent-
age is remaining stable. New cases of HIV have not
been diagnosed among young drug users.
The Centre for Treatment of Drug Dependencies in
Bratislava (Slovakia) implements a comprehensive
programme based on the education of drug users,
testing drug users for blood-borne infections, vaccina-
tion against hepatitis B, a needle distribution
programme and a methadone-maintenance programme.
All these programmes were fully functional at the
beginning of 1998. All clients with negative HBV
markers are vaccinated against HBV. Between 1997
and 2001,1 817 users, mostly from Bratislava, were
involved in this programme. During the same period,
HIV prevalence among IDUs has remained almost at
zero, the prevalence of HBV has remained low and
HCV prevalence has remained below 40 % over the
last three years.
Two correlation studies are available indicating the
influence that provision of sterile injecting equipment
has had on the spread of DRIDs among IDUs. A
regional analysis of the data on HIV infection rates in
Poland between 1990 and 1995 showed a statistically
significant impact of the syringe exchange
programmes. Those regions with higher rates of
syringe distribution were found to have lower rates of
HIV infection. Similarly, the higher volumes of
syringes exchanged within Czech districts was related
to the lower reported incidence of HCV and to the
positive changes in this incidence during the period
1998 to 1999.
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The drug market and drug-related
criminality
Changes in domestic markets
Shift from locally produced drugs 
to ‘international’ substances
The drug problem is a relatively recent phenomenon in
most of the CEECs, as it only started in the 1990s. Even
where the problem started earlier, as in Poland, the extent
and nature of the problem changed significantly in the
1990s. At present, the drug scene in the CEECs increasingly
resembles that of western Europe.
In Poland in the 1970s and 1980s, and in Estonia, Latvia
and Lithuania in the late 1980s, home-made opiates were
produced by drug users from poppy straw. It is inaccurate to
describe this as a ‘market’ as the ‘Polish heroin’ was
produced by drug users for personal use and only the
surplus was sold. In the Czech Republic, the drug scene was
dominated by pervitin — the Czech metamphetamine, also
produced domestically. The local drug markets were not
connected with international ones, so international organ-
ised crime was not involved. 
The situation has diametrically changed in the 1990s. New
drugs such as amphetamines, cannabis, LSD, ecstasy,
cocaine and heroin brought organised criminal groups into
the drugs arena, and the market was developed with
connections to international markets.
The transit and production role of the CEECs has facili-
tated the creation of domestic markets, thus contributing,
to some extent, to the growth of the drug problem in the
region. However, the increase in drug consumption in the
region is not only determined by supply but also by
demand for drugs, and it seems that this second factor
plays a more important role. Central eastern European
youth consider recreational drug use to be part of a
western lifestyle, and this is therefore seen as attractive. As
the results of a qualitative study in Poland show, cannabis
and synthetic drugs are becoming a common feature of
youth culture. It seems that the drug supply only satisfies
the demands that result from these cultural influences.
According to drug seizures data, the drug market is
expanding. These figures cover seizures by all law-
enforcement agencies dealing with drugs, such as the
police, customs, border guards, special drug agencies,
etc., which vary from country to country. The figures
include confiscation of drugs on the street as well as at
the wholesale level. The available data, however, do
not differentiate between drug seizures on the domes-
tic market and seizures of drugs in transit. It is also
difficult to distinguish which come from the whole-
salers and producers and which come from the
consumers and dealers. Therefore, data on drug
seizures can only provide a very general picture of
changes in the market.
The increasing trend in both the number of seizures
and the quantities of particular drugs varies from
country to country. The figures fluctuated over time,
but the same trend of increase could be identified in
most cases, especially in the number of seizures. The
numbers, however, are fairly small, which means they
are sensitive to random fluctuation. The figures for the
quantity of drugs are even more sensitive, because just
one relatively large seizure can have quite a marked
effect. The rising trend in drug seizures may simply
reflect changes in the actions of law-enforcement
agencies rather than changes in the extent of the drug
problem. However, sometimes the trend of drug
seizures can provide an indication about changes in
the drug scene. For example, it seems that heroin
appeared on the Baltic states markets later than it did
in the other markets in the region (Figure 20). 
Over the last three years, there has been a far greater
increase in heroin seizures in Estonia and Lithuania
(especially Estonia) than in other countries of the
region. Heroin seizures in those two countries have
also increased more than seizures of other drugs. This
could be interpreted as a homogenisation of the drug
scene in the region, bringing them more in line with
the western drug scene.
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Source: 2001 CEEC national reports.
Figure 20: Trend in number of seizures of heroin 
(Index 1998 = 100)
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Quantity of drugs seized in kg Number of seizures
1996 1997 1998 1999 2000 1996 1997 1998 1999 2000
Bulgaria (1)
Cannabis 14195.86 13.380 752.012 0.019 687.164 4 3 7 3 19
Heroin 195.471 311.618 158.002 261.567 1860.987 24 23 20 15 45
Cocaine 14.288 1.020 685.155 13.08 2.610 4 2 8 5 6
Amphetamine 0 222.346 0 0 32.530 0 1 0 0 3
Czech Republic
Cannabis 12000 5.5 5.5 112.4 39.75 5 14 19 131 517
Heroin 20 3.4 147.3 108.38 114.52 12 10 14 19 34
Cocaine 22 62.5 41.3 140.8 14.71 3 2 4 3 28
Amphetamine 21 0 4.1 0.72 2 0 1 12 18
Estonia
Cannabis 7.754 3.962 28.106 44.632 81.75 85 71 147 182 223
Heroin - - 0.091 0.518 0.438 0 0 18 129 249
Cocaine 0.002 0.006 2.565 0.128 0.108 4 10 35 26 22
Amphetamine 1.103 0.69 1.881 10.813 26.692 29 37 126 164 207
Hungary
Cannabis 862 2342 151.8 100.5 131 345 770 1340 2029 2295
Heroin 319.2 206.1 937 172.7 819 145 177 423 688 688
Cocaine 8 7.6 20 115 10.9 59 86 132 152 190
Amphetamine 0.5 12.7 10.3 4.6 10.5 198 490 720 569 408
Lithuania
Cannabis 0.826 8.63 30.357 25.667 n.a. 5 13 45 70 n.a.
Heroin - 0.089 0.423 0.923 n.a. 0 2 6 34 n.a.
Cocaine 1.056 2.049 10.133 0.275 n.a. 2 2 11 16 n.a.
Amphetamine 0.054 0.171 0.013 0.077 n.a. 2 8 12 29 n.a.
Slovakia
Cannabis 24.8 874.1 15377 849.5 234.3 252 161 378 399 619
Heroin 10.6 90.4 13.7 5.8 98.5 687 1086 567 401 604
Cocaine n.a. 9.6 1.6 2.5 0.2 19 15 18 29 25
Amphetamine n.a. n.a. 9.7 0.1 1.1 20 19 44 51 101
Cannabis seizures have also increased in recent years,
particularly in the Czech Republic, Estonia and
Hungary. However, the amount of cannabis seized has
decreased. This may be because resources are being
targeted by local law-enforcement agencies at street
level (making arrests of dealers and users) rather than
focusing on traffickers and major dealers.
Shift in patterns 
of use and the drug culture
In Poland, which has a relatively long history of drug
use, using drugs was initially part of the hippie ideol-
ogy of the 1970s and was later incorporated into other
subcultures. In the 1980s, drugs were used — without
any ideological justification — for their psychoactive
properties alone. In response to law-enforcement
measures, groups of drug users began to organise
themselves and it is in this context that a subculture of
(1) Seizures by customs only.
Table 9: Drug seizures in the CEECs
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drug use started to develop and the symbols, norms and
customs typical of drug users’ groups began to emerge.
Drug user circles were quite hermetic at that time. Due
to the pharmacological properties of home-made
opiates, users rapidly became dependent and social
marginalisation soon followed. Although the drug
subculture was an attractive alternative for some, fear,
repulsion or compassion were more common reactions
than the wish to join it. The primitive nature of the
drugs used then, together with injecting, HIV infection
and rapid social degradation and health impairment,
discouraged most people from following that path.
The situation has changed rapidly during the 1990s.
New substances have appeared on the drug scene that
need not be injected and have the image of being
‘clean’, sophisticated and harmless — characteristics
which have markedly increased the attractiveness of
the ‘drug use’ experience. Over time, understanding of
the advantages and risks associated with using particu-
lar drugs has improved, and a picture of those using
them has emerged. Young people who began experi-
mentation with drugs in the 1990s or after are, in many
ways, different from those who began using drugs in
earlier decades. Drug use is now relatively common
behaviour related to leisure, rather than deviant
behaviour associated with socially maladjusted youth.
The world of adults has not been able to stop this
process, probably partly because of the profound
nature of the transformation of societies in the region
and its consequences. Rapid social change involving
the destruction of social structures and the introduc-
tion of entirely new economic and political systems
has significantly altered the relationship between
generations. The struggle of adapting to the new reality
has rendered many parents incapable of giving
adequate guidance to their children. Young people,
who are often as confused as their parents, are faced
with conflicting values, norms and lifestyles. Western
cultural patterns are seen as particularly attractive,
where commitment or obligations are scorned and
self-gratification is actively promoted. Those drugs
which are considered sophisticated and safe fit well
with such a scenario.
Changes in patterns of drug use are dictated to some
extent by fashion. Fashions in drug use are frequently
related to other aspects of leisure and entertainment —
new trends in music, in particular. For example, this
was the case with ecstasy, which was associated with
techno music, and heroin, which was associated with
hip-hop. Drugs that enter the market in connection
with specific trends in youth culture tend to gain a
wider base of users over time.
Availability of drugs
Drug availability is one of the factors influencing drug
consumption. It can be considered in terms of individ-
ual access to drugs and in terms of supply and price.
Individual availability is dependent not only on the
amount of drugs on the market but also on the way the
market functions. For example, according to a qualita-
tive study in the Polish city, Poznan, it is very difficult to
buy drugs there without knowing a dealer or being
recommended, while in cities like Warsaw or Krakow,
there are open street markets available to all. The avail-
ability of new technologies also makes it possible to
purchase and sell drugs by mobile phone or the Internet. 
The perceived availability of drugs by potential
consumers may be an indicator of actual availability. In
population or school surveys, for example, respondents
are often asked to assess how difficult it would be for
them to obtain particular substances or they are asked
for their opinion on the general availability of drugs. An
indicator constructed in this way could be a useful
supplementary tool for assessing changes in availability.
According to the results of the 1995 and 1999 ESPAD
school surveys, perceived drug availability varies
greatly from country to country in the region. School
students were asked to assess how easy it would be for
them to buy a particular drug.
In all participating CEECs, significant differences in
responses can be observed between 1995 and 1999. The
percentage of students perceiving particular drugs to be
‘easy’ or ‘very easy’ to obtain increased considerably.
Examining the data for cannabis and ecstasy, the graph
shows a higher increase in countries where the percent-
ages were lower in 1995, such as the Baltic states and
Hungary. In some countries, such as Poland and, in
particular, Estonia, the perceived availability of ecstasy
increased more than cannabis, while in Lithuania the
opposite was the case (see Figures 21 and 22).
Price is an important factor in drug availability. Since
countries differed in how they collected drug-price data,
the price of a particular drug is not comparable between
countries, but price structure could still be compared.
Comparison is made even more difficult because price
data on some drugs is missing in a number of countries.
Figure 23 highlights both similarities and differences
between countries in their drug price structures. Cocaine
and heroin prices vary widely from country to country.
Cocaine is generally the most expensive drug, with heroin
usually in second place. However, in Estonia and Latvia,
heroin occupies first place. In Poland, cocaine is slightly
more expensive than white heroin, but in the Czech
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Republic it is more than twice the price. While marihuana is
the cheapest drug in all countries, significant price differ-
ences still exist from country to country for marihuana and
hashish, it being cheapest in Hungary and most expensive
in the Czech Republic. The relatively high price of heroin in
Latvia and Estonia could be due to its fairly recent appear-
ance on local markets.
Only Hungary and the Czech Republic have collected data
on drug prices over a longer period of time, but the method-
ology of collection may be open to question. Hungarian
figures for 1996 to 2000 show an increase in the price of all
drugs, and this is particularly evident from 1999 on. Data
from the Czech Republic for the corresponding period
show drug prices remaining stable. Qualitative information
from the other CEECs, gathered over a shorter time period,
suggest drug prices have remained stable in recent years.
In summary, the increase in perceived availability,
combined with stability in prices, support the contention
that there is no decrease in drug availability. At the same
time, this could be interpreted as an illustration of certain
limitations of supply-reduction strategies in the region.
Traffic and transit of drugs 
across the region
CEECs are an important drug-transit area, particularly in
relation to the European Union. For example, 97 % of
drugs seized by Bulgarian customs was destined for the
consumer markets in central and western Europe.
However, as drug consumption increases, it seems that
the CEECs are increasingly becoming targets for distribu-
tion as well.
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NB: Percentage of students who thought it easy or very easy.
Source: ESPAD.
Figure 22: Perceived availability of ecstasy according to ESPAD
NB: Percentage of students who thought it easy or very easy
Source: ESPAD.
Figure 21: Perceived availability of marihuana or hashish according to ESPAD
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The region plays a central role as a transit area in
heroin trafficking. Heroin is smuggled into the whole of
Europe from Afghanistan, Iran, Pakistan and Turkey
through Bulgaria, the former Yugoslav republics,
Romania and Hungary — the so-called ‘Balkan route’
— and from the central Asian states through Russia, the
Ukraine, Poland and the Baltic states along the so-
called ‘silk route’. Law-enforcement agencies estimate
that at least 80 % of the heroin available in Europe is
transported along the Balkan routes. CEECs are used to
storing heroin destined for secondary distribution in the
European Union. Albania is being used increasingly as
a transit country for heroin trafficking, mostly to Italy
and Greece.
The Balkan route is used in the opposite direction to
smuggle the chemicals used in heroin processing. In
1999, Operation Purple, a voluntary international anti-
trafficking programme, was initiated to prevent the
distribution of potassium permanganate. Poland,
Hungary and Bulgaria have been actively involved in
identifying smuggling routes and dismantling trafficking
networks. In addition, Operation Topaz, which
commenced in March 2001, has been successful in
inhibiting the trafficking of acetic anhydride when law-
enforcement agencies successfully identified trafficking
routes through Romania and Bulgaria (International
Narcotics Control Board, 2001).
According to the United Nations Office for Drug
Control and Crime Prevention (UNODCCP), 80 % of
heroin consumed in western Europe comes from
Afghanistan and Pakistan. Half of this drug (about 120
tons of heroin equivalent) comes to Europe via central
Asia and eastern and central Europe. During 2000,
Germany’s role in the ‘silk route’ was probably
NB: Prices of ecstasy per tablet, other substances per gram.
Source: 2001 CEEC national reports.
Figure 23: Prices of drugs in Euro in 2000 
reinforced, since it is not only a consumer country but
also a significant gateway en route to the consumer
markets of the European Union. 
Synthetic drugs, mostly amphetamines, are smuggled
from Poland, the Czech Republic, Lithuania, Latvia and
Estonia either directly to the Nordic countries or else
across the Baltic states. Amphetamines are also trans-
ported to Germany. Ecstasy is transported from the west,
mostly the Netherlands, to CEECs, although its traffick-
ing also occurs to some extent in the opposite direction
(from Poland to Austria or Germany, for example). Baltic
states like Estonia are points of transit for synthetic drugs
from western and central Europe to the Scandinavian
countries. According to the UNDCP, ‘ampethamine-
type substances (ATS) seizures are also reported from
eastern Europe, notably from Bulgaria, Poland, the
Russian Federation, the Czech Republic, Estonia and
Hungary, which accounted together for 98 % of all ATS
seizures in east Europe’ (Global illicit drug trends,
2001).
Cannabis, mostly with a high THC (tetrahydrocannabi-
nol) content, crosses the European Union to the CEECs,
while herbal cannabis from Albania is destined for the
European Union, notably Greece and Italy. Cannabis is
also smuggled through the Baltic states, for example
from Spain through Estonia to the Nordic countries.
The region is also beginning to play a role in cocaine
trafficking. The drug sometimes travels in a roundabout
fashion to European Union countries in order to avoid
the vigilance of police and customs officers. Cocaine is
sometimes shipped from Latin America to ports in the
CEEC and then on to the west. Cocaine destined for
western Europe has been seized in Poland, Bulgaria,
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Estonia, Lithuania and Albania. Sometimes the cocaine is
stored in transit countries prior to further distribution in
the Europe Union.
In summary, the region serves not only as a point of
transit for the west of the continent — this as a result of
its geographical location — but it also is beginning to
form a common drugs market with the western European
countries. 
The region as a producer 
and potential exporter 
In some CEECs, the production of traditional drugs is
ongoing, though its extent varies. In Poland, produc-
tion of ‘Polish heroin’ has diminished due to a decreas-
ing demand for the drug, as well as due to increased
difficulty in acquiring the poppy plants. A move to
low-opium poppy cultivation has considerably limited
supply and virtually no cases of attempted export of
the drug to other countries have been recorded. This is
in marked contrast to the case of pervitin in the Czech
Republic, where production continues both for inter-
nal use and export, particularly to Germany, Austria
and Slovakia.
The region is now beginning to produce drugs commer-
cially for the first time. At present this appears to be
mostly limited to synthetic drug production and
cannabis cultivation. Synthetic drugs were initially
developed for export to the Nordic states and Germany,
but latterly they are being produced for domestic
consumption too. 
Synthetic drug production has grown, due to weak
regional control mechanisms. The initial lack of aware-
ness, experience and proper legal regulation in the CEECs
has created an ideal atmosphere for the development of
illegal laboratories. Lack of controls on the precursors,
especially, has aided illegal production. In the early
1990s, there were even attempts to produce drugs
synthetically in official chemical and pharmaceutical
factories. Poland was the first of the CEECs to produce
amphetamines, but nowadays there are illegal laborato-
ries in Bulgaria, Hungary, the Czech Republic and the
Baltic states. In 2000, illegal laboratories producing PMA
and PMMA for consumer markets in western Europe were
uncovered in Poland. In Poland, Bulgaria and Estonia,
laboratories producing ecstasy have also been disman-
tled.
Cannabis is cultivated primarily for domestic use, but, in
the case of Albania, it is also exported.
Drugs and crime 
Drug use and criminal activity are interconnected and the
nature of this connection is very complicated. Generally
speaking, drug-related crime includes any criminal activ-
ity that is committed either to fund, or as a consequence
of, drug use.
In Tackling drugs together - a strategy for England
1995–1998, several types of drug-related offences are
distinguished. These include:
• all offences covered by a country’s drug legislation
(e.g. trafficking, production, using, supplying, etc.);
• criminal acts by persons as a consequence of drug
misuse;
• acquisitive crime (such as theft, burglary and fraud) to
finance drug misuse;
• laundering of drug-trafficking profits, either to fund
further drug trafficking or to allow unrestricted use of
assets; and
• violent crime carried out in the course of drug distri-
bution and trafficking (for example, violence between
dealers or against innocent parties).
Legislation and changes in legislation 
How crimes relating to drug use or supply (such as
production, trafficking, distribution and possession, the
promotion of drug use and money laundering) are viewed
is very dependent on the law of the country in question.
Drug control legislation in the CEECs varies from country
to country, both in its scope and attitude towards repres-
sion. In some countries, drug possession is penalised
regardless of the amount involved and whether or not it is
for personal use. This is the case, for example, in the
Czech Republic, Lithuania, Hungary, Poland, Romania
and Slovakia. Other countries do not regard possession of
small quantities for personal use as an offence. In Estonia,
first-time possession, or purchase of small quantities of
drugs for personal use, is considered an administrative
offence and is not prosecuted. A second similar misde-
meanour committed within 12 months is penalised in
accordance with the Criminal Code. In Slovenia, posses-
sion of small quantities of illegal drugs for personal use is
considered a misdemeanour and merits a fine or prison
sentence of up to five days. In Bulgaria, possession for
personal use in the case of drug addicts is not punishable.
Drug-related criminality, which appears to be on the
increase, determines to a large extent the scale and intensity
of repressive measures. In the late 1990s, new harsher laws
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were adopted in the Czech Republic, Poland, Lithuania,
Romania and Slovakia. These changes in the law make
analysis of trends more difficult, as greater repression could
increase the number of offences recorded. 
Offences against the drug laws 
Law-enforcement data on drug-related offences show an
increase in almost all CEECs (Figure 24).
A decreasing trend (since 1997) has only been noted in
Slovakia, which is related to a Supreme Court ruling on
drug law. In the Czech Republic, the trend was going up
until the end of 1999, but the following year, 2000,
showed a decrease due to changes in the reporting
system. Estonia had the largest increase in the number of
registered drug-related offences, a 13-fold increase
between 1996 and 2000. Slovenia had the least, with
two-and-a-half times more.
The main offences dealt with by police are possession,
use, encouragement to use and retail sale of drugs. In
Estonia, for example, offences associated with use or
possession of drugs (without intent of trafficking) amount
to 80 % of all drug-related offences registered by police.
In Slovenia, between 1996 and 2001, the number of
drug-related misdemeanours increased 3.7 times (4 352
in total), while the number of drug-related crimes
increased 2.3 times (1 537 in total). In Poland, 82 % of all
drug-related offences involve possession, sale or use.
Detection and prosecution of wholesale trafficking, large-
scale production and laundering of drug money is
relatively rare. Law-enforcement agencies, therefore, are
not able to influence the drug market significantly in the
long-term. At best, a limited impact on local markets for a
short time is achieved.
With crime figures on the rise in almost all CEECs, a large
influx of drug users can be expected in correctional facili-
ties, causing additional demands on state budgets. In
Poland, for example, study results show that drugs are
available and used within the prison system. In fact, some
people first use drugs when detained in a penal institution.
Offences committed by drug users
It is difficult to assess the extent of criminality among drug
users. Statistical data have generally not been collected, nor
surveys undertaken, by the CEECs. One exception to this is
the Czech survey 'The Impact Analysis Project of New Drug
Legislation' (known as the PAD study), which estimated the
proportion of drug-related criminal activity (Zabransk´y et
al., 2001). The results show that the most common offences
are those against property (theft, burglary and robberies).
This study was ordered by the Czech government after an
amendment to drug laws introduced punishment for drug
possession for personal use. The research combined quanti-
tative and qualitative methodology and made extensive use
of the EMCDDA harmonised key epidemiological indica-
tors. The study results showed the social and monetary
losses arising from this legislation. Following the study
findings, the Czech government defined six concrete steps
in order to improve the situation.
A qualitative study conducted in Poland among ‘street-level
drug users’ showed that petty offences are common.
Offences against property, particularly among drug addicts
using Polish heroin, were the commonest. Violence was
reported more often among drug addicts using ‘new’ drugs
like amphetamines. In some ways, this mirrors societal
transformation, with increasing violence in interpersonal
relations becoming commonplace. Young people are
surrounded by violence, both from peers and adults, and
this is also apparent in the world of drugs. 
A Hungarian study carried out in 2001 focused on
enforcement by the judicial authority in cases of drug
offences in order to determine if the provisions of the
Penal code (in effect from 31 March, 1999) would
achieve its social goals and impact on drug policies. 
Organised crime 
The appearance of ‘new’ drugs in the 1990’s (heroin,
amphetamines, cannabis, LSD, ecstasy, and ultimately
cocaine) in the CEECs paralleled the appearance of
organised criminal groups. The market developed
through connections to the international market.
Large-scale drug production and trafficking is increas-
ingly becoming the domain of international criminal
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Source: 2001 CEEC national reports.
Figure 24: Numbers of drug-related offences registered by the police
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groups and local drug distribution is controlled by organ-
ised crime gangs that would previously have been
involved in theft and smuggling of cars, alcohol and
cigarettes. New criminal groupings have also emerged in
the drugs business. The fight for control of the developing
drugs market has become very vicious, with the use of
guns and explosives being seen for the first time.
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Capture–recapture method: Sophisticated statistical
method using different sources of data in order to identify
overlaps and consequently estimate hidden populations.
First treatment demand: Number of people (or percentage
of population) seeking drug-related treatment for the first
time in a given period.
High-threshold treatment: A ‘drug-free’ treatment aimed
at achieving total abstinence from any (illicit) drug as
soon as possible. With the exception of detoxification,
the patient has to be drug free before entering the
programme/treatment.
Lifetime prevalence: Number of people (or percentage of
population) who have used any illicit drug at least once
in their lifetime.
Low-threshold treatment: Treatment that is not solely
focused on the goal of total abstinence and does not insist
that clients/patients are drug free before entering the treat-
ment/programme. An important focus of low-threshold
services is the general health and safety of the user, and a
wide range of measures are used to achieve this, including
nutritional and vitamin advice, needle exchange
programmes and education about safer patterns of drug use.
Prevalence of current use: Number of people (or percent-
age of population) who have used any illicit drug during
the last month.
Prevalence of last year use: Number of people (or
percentage of population) who have used any illicit drug
in the last year.
Problem drug use: Intravenous drug use (IDU) or long
duration/regular use of opiates, cocaine and/or ampheta-
mines. Ecstasy and cannabis are not included in this
category.
Treatment: This term is used to define the process that
begins when problem drug users come into contact with
a health provider or other community service. Treatment
may continue through a succession of specific interven-
tions until the highest attainable level of health and well-
being is reached (WHO et al., 2000).
Treatment demand: Number of people (or percentage of
population) receiving drug-related treatment in a given
period, whether they have received treatment before or not.
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Bulgaria
Secretariat of the National Drugs Council
Ministry of Health
39 Stamboliski Blvd. 
Sofia 1000 — Bulgaria
Tel: (359-2) 930 13 00 
Fax: (359-2) 930 11 88
E-mail: NDC@abv.bg
Legal base
Appointed by the Minister of Health, who is also chairman of the
National Drugs Council (NDC).
Czech Republic 
Secretariat of the National Drug Commission
Office of the Government of the Czech Republic
Nabr. Edvarda Benese 4
118 01 Praha 1 — Malá Strana — Czech Republic
Tel: (420-2) 96 15 32 22
Fax: (420-2) 96 15 32 64
E-mail: mravcik.viktor@vlada.cz
Legal base
Governmental resolution No. 643 of 19 June 2002 constituted the
National Focal Point for Drugs and Addictions in the Secretariat of
the Governmental Council for Drug Policy Co-ordination (formerly
the National Drug Commission).
Estonia
Estonian Drug Monitoring Centre
Institute of Experimental and Clinical Medicine (IECM)
Hiiu 42
EE 11619 Tallinn — Estonia
Tel: (372) 670 70 99
Fax: (372) 670 68 14
E-mail: ave.talu@ekmi.ee
Legal base
Decree of the Minister of Social Affairs No. 204 of 24 May 2001
established the Estonian Drug Monitoring Centre at the Estonian
Institute of Experimental and Clinical Medicine (under the Ministry
of Social Affairs) as a national focal point to the EMCDDA.
Hungary 
Ministry of Health, Social and Family Affairs
Arany János u. 6–8
H – 1245 Budapest
P.O. Box 487
Tel: (36-1) 332 31 00
Fax: (36-1) 269 40 07
E-mail: liptak.jozsef@eum.hu
Legal base
Pending a governmental resolution, functions of NFP assigned to
the Ministry of Health, Social and Family Affairs.
Latvia
State Centre for Drug Abuse Prevention and Treatment
Ministry of Health
Hospitalu iela 55
Riga LV 1013 — Latvia
Tel: (371-7) 37 46 81
Fax: (371-7) 37 23 37
E-mail: ieva.berzina@latnet.lv
Legal base
Appointed by the Minister of the Interior, who is also the chair-
man of the Drug Control and Drug Abuse Combat Coordination
Commission.
Lithuania
State Public Health Service
Kalvariju 153 
LT-2001 Vilnius — Lithuania
Tel/Fax: (370-2) 66 14 63
E-mail: audrone.astrauskiene@vvspt.lt
Legal base
Order of the Ministry of Health [of 5 April 2002 established the
national focal point to the EMCDDA in the State Public Health
Service.
Poland 
National Bureau for Drugs Prevention 
Dereniowa 52/54
02-776 Warsaw — Poland
Tel: +48 22 641 15 01
Fax: +48 22 641 15 65
E-mail: sierosla@ipin.edu.pl
Legal base
Act of Law of 6 September 2001 amending the Act on Counteracting
Drug Addiction and other acts of law; Journal of Laws, 2001, No.
125, item 1367, dated 30 October 2001, entrusts the National
Bureau for Drug Prevention of the Ministry of Health with monitor-
ing the drug problem (data collection, analysis and reporting).
Romania
Institute of Health Services Management
31 Vaselor, Sector 2
73258 Bucharest — Romania
Tel: (401) 252 78 34 
Fax: (401) 252 30 14
E-mail: bmartian@hotmail.com
Legal base
Appointed by the Ministry of Heath and the Ministry of the Interior. 
Slovakia
Central Node of the Drug Information System
General Secretariat of the Board of Ministers for Drug
Dependencies and Drug Control
Námestie slobody 1
81370 Bratislava — Slovakia
Tel: (421-2) 57 29 57 32
Fax: (421-2) 52 49 16 94
E-mail: alojz.nociar@government.gov.sk
Legal base
Governmental resolution No. 534 of 22 May 2002 established the
National Monitoring Centre for Drugs (NMCD) as an independent
department at the government office serving as a focal point to the
EMCDDA; it is also a member of the European Information
Network on Drugs, Reitox.
Slovenia
Institute of Public Health 
Trubarjeva 2
SI — 1000 Ljubljana — Slovenia
Tel: (386-1) 244 14 90
Fax: (386-1) 244 14 47
E-mail: Mercedes.lovrecic@ivz-rs.si
Legal base
The Prevention of Illicit Drug Abuse and Treatment of Drug
Addictions Law (1999) provides for the establishment of an infor-
mation unit for illegal drugs; Order of the Minister of Health of
March 2001 established the Information Unit for Illegal Drugs and
its national focal point to the EMCDDA at the Institute of Public
Health of the Republic of Slovenia.
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